WO2022076750A2 - Recombinant adeno-associated viruses for cns or muscle delivery - Google Patents
Recombinant adeno-associated viruses for cns or muscle delivery Download PDFInfo
- Publication number
- WO2022076750A2 WO2022076750A2 PCT/US2021/054058 US2021054058W WO2022076750A2 WO 2022076750 A2 WO2022076750 A2 WO 2022076750A2 US 2021054058 W US2021054058 W US 2021054058W WO 2022076750 A2 WO2022076750 A2 WO 2022076750A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- capsid
- aav
- aav9
- seq
- raav
- Prior art date
Links
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 69
- 210000003205 muscle Anatomy 0.000 title claims description 20
- 238000012384 transportation and delivery Methods 0.000 title description 29
- 210000000234 capsid Anatomy 0.000 claims abstract description 489
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 149
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract description 149
- 238000010361 transduction Methods 0.000 claims abstract description 130
- 230000026683 transduction Effects 0.000 claims abstract description 129
- 238000006467 substitution reaction Methods 0.000 claims abstract description 126
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 98
- 230000001965 increasing effect Effects 0.000 claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 168
- 210000004027 cell Anatomy 0.000 claims description 158
- 238000003780 insertion Methods 0.000 claims description 127
- 230000037431 insertion Effects 0.000 claims description 127
- 210000001519 tissue Anatomy 0.000 claims description 97
- 108700019146 Transgenes Proteins 0.000 claims description 96
- 239000013608 rAAV vector Substances 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 69
- 210000004185 liver Anatomy 0.000 claims description 60
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 239000008194 pharmaceutical composition Substances 0.000 claims description 47
- 210000003594 spinal ganglia Anatomy 0.000 claims description 45
- 230000008685 targeting Effects 0.000 claims description 45
- 230000001225 therapeutic effect Effects 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 230000010354 integration Effects 0.000 claims description 33
- 230000014509 gene expression Effects 0.000 claims description 32
- 210000002027 skeletal muscle Anatomy 0.000 claims description 27
- 238000004806 packaging method and process Methods 0.000 claims description 23
- 239000013607 AAV vector Substances 0.000 claims description 22
- 210000004165 myocardium Anatomy 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 16
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 16
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 15
- 230000003247 decreasing effect Effects 0.000 claims description 14
- 208000015114 central nervous system disease Diseases 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 208000029578 Muscle disease Diseases 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 7
- 210000002363 skeletal muscle cell Anatomy 0.000 claims description 7
- 210000005229 liver cell Anatomy 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 210000000578 peripheral nerve Anatomy 0.000 claims description 6
- 208000019622 heart disease Diseases 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 claims description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 5
- 210000000663 muscle cell Anatomy 0.000 abstract description 5
- 239000013598 vector Substances 0.000 description 101
- 235000001014 amino acid Nutrition 0.000 description 99
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 60
- 210000003169 central nervous system Anatomy 0.000 description 51
- 239000003795 chemical substances by application Substances 0.000 description 51
- 150000001413 amino acids Chemical group 0.000 description 48
- 241001465754 Metazoa Species 0.000 description 44
- 229940024606 amino acid Drugs 0.000 description 44
- 238000001990 intravenous administration Methods 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 38
- 210000004556 brain Anatomy 0.000 description 37
- 230000008499 blood brain barrier function Effects 0.000 description 36
- 210000001218 blood-brain barrier Anatomy 0.000 description 36
- 239000000203 mixture Substances 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 31
- 201000010099 disease Diseases 0.000 description 30
- 208000035475 disorder Diseases 0.000 description 30
- 239000002245 particle Substances 0.000 description 30
- 238000011282 treatment Methods 0.000 description 30
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 29
- 241000282567 Macaca fascicularis Species 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 28
- 230000000069 prophylactic effect Effects 0.000 description 28
- 239000005090 green fluorescent protein Substances 0.000 description 26
- 230000003612 virological effect Effects 0.000 description 26
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 24
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 24
- 238000012986 modification Methods 0.000 description 23
- 230000004048 modification Effects 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 22
- 239000003814 drug Substances 0.000 description 21
- 238000010586 diagram Methods 0.000 description 17
- 125000000539 amino acid group Chemical group 0.000 description 16
- 210000002216 heart Anatomy 0.000 description 16
- 238000007481 next generation sequencing Methods 0.000 description 16
- 229940124597 therapeutic agent Drugs 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 238000009826 distribution Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 238000003753 real-time PCR Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000001320 hippocampus Anatomy 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 13
- 238000000185 intracerebroventricular administration Methods 0.000 description 13
- 230000010415 tropism Effects 0.000 description 13
- 235000004279 alanine Nutrition 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 230000002093 peripheral effect Effects 0.000 description 12
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 235000009582 asparagine Nutrition 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 10
- 150000001295 alanines Chemical class 0.000 description 10
- 150000001508 asparagines Chemical class 0.000 description 10
- 210000005153 frontal cortex Anatomy 0.000 description 10
- 238000001415 gene therapy Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000001638 cerebellum Anatomy 0.000 description 9
- 230000003472 neutralizing effect Effects 0.000 description 9
- 230000002463 transducing effect Effects 0.000 description 9
- 241000701161 unidentified adenovirus Species 0.000 description 9
- 101150044789 Cap gene Proteins 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000005100 tissue tropism Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 210000001259 mesencephalon Anatomy 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 238000011887 Necropsy Methods 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 210000003497 sciatic nerve Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000000115 thoracic cavity Anatomy 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000008827 biological function Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000001476 gene delivery Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 201000006938 muscular dystrophy Diseases 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 241000958487 Adeno-associated virus 3B Species 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 206010011906 Death Diseases 0.000 description 4
- 102100035426 DnaJ homolog subfamily B member 7 Human genes 0.000 description 4
- 101100285903 Drosophila melanogaster Hsc70-2 gene Proteins 0.000 description 4
- 101100178718 Drosophila melanogaster Hsc70-4 gene Proteins 0.000 description 4
- 101100178723 Drosophila melanogaster Hsc70-5 gene Proteins 0.000 description 4
- 101000804114 Homo sapiens DnaJ homolog subfamily B member 7 Proteins 0.000 description 4
- 101150090950 Hsc70-1 gene Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 101100150366 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sks2 gene Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- 241000649045 Adeno-associated virus 10 Species 0.000 description 3
- 241000649046 Adeno-associated virus 11 Species 0.000 description 3
- 241000649047 Adeno-associated virus 12 Species 0.000 description 3
- 241000300529 Adeno-associated virus 13 Species 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 238000009593 lumbar puncture Methods 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 238000009126 molecular therapy Methods 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 230000002276 neurotropic effect Effects 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 101150066583 rep gene Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000009039 Axonemal Dyneins Human genes 0.000 description 2
- 108010049197 Axonemal Dyneins Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000702623 Minute virus of mice Species 0.000 description 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 2
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 208000025014 late infantile neuronal ceroid lipofuscinosis Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000005244 lower chamber Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000022587 qualitative or quantitative defects of dystrophin Diseases 0.000 description 2
- 239000013646 rAAV2 vector Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000031998 transcytosis Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 241000649044 Adeno-associated virus 9 Species 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100030942 Apolipoprotein A-II Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 101100412102 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) rec2 gene Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101000793406 Homo sapiens Apolipoprotein A-II Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 1
- 101000640899 Homo sapiens Solute carrier family 12 member 2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108091007780 MiR-122 Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- -1 TWEENTM Substances 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000007845 axonopathy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 102000013035 dynein heavy chain Human genes 0.000 description 1
- 108060002430 dynein heavy chain Proteins 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000001905 globus pallidus Anatomy 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000001308 heart ventricle Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000009540 indirect ophthalmoscopy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000011451 sequencing strategy Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000006107 tyrosine sulfation Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins with one or more amino acid substitutions and/or peptide insertions that confer and/or enhance desired properties, including tissue tropisms.
- rAAVs adeno-associated viruses
- the invention provides engineered capsid proteins comprising one or more amino acid substitutions or peptide insertions that enhance the tropism of an AAV serotype for one or more tissue types as well as capsids that are not engineered but are found to confer muscle or CNS tropisms on rAAVs.
- the one or more amino acid substitutions and/or insertions in the AAV capsid improve transduction, genome integration and/or transgene expression in heart and/or muscle tissue or the central nervous system while reducing tropism for the liver and/or the dorsal root ganglion and/or peripheral nerve cells.
- rAAVs having the capsid proteins disclosed herein are useful for delivering a trans gene encoding a therapeutic protein for treatment of CNS or muscle disease.
- AAV adeno-associated viruses
- recombinant AAVs have been used as gene transfer vectors, in which therapeutic sequences are packaged into various capsids. Such vectors have been used in preclinical gene therapy studies and over twenty gene therapy products are currently in clinical development.
- Recombinant AAVs such as recombinant AAV9 particles, have demonstrated desirable neurotropic properties and clinical trials using recombinant AAV9 for treatment of CNS disease are underway. Delivery to muscle and/or heart tissue is also desirable. Reduction of transduction of liver and/or dorsal root ganglion cells may also be desirable to reduce toxicity.
- attempts to enhance the neurotropic or muscle/heart tropic properties of rAAVs in human subjects have met with limited success.
- rAAV vectors with enhanced neurotropic or with tropism for muscle and/or heart properties for use, e.g., in treating disorders associated with the central nervous system or where expression in the heart and/or muscle are desirable, with minimal transduction in liver and/or dorsal root ganglion cells and/or peripheral nerve cells to minimize adverse effects.
- rAAV vectors with enhanced tissue-specific targeting and/or enhanced tissue-specific transduction to deliver therapies are also is a need.
- rAAVs recombinant adeno-associated viruses
- capsid proteins engineered to have one or more amino acid substitutions and/or peptide insertion that enhance tissue targeting, transduction and/or integration of the rAAV genome in CNS and/or muscle tissue relative to a reference capsid, for example, the parent capsid or an AAV8 or AAV9 capsid, while having reduced biodistribution in certain tissues, such as liver and dorsal root ganglion cells, relative to the distribution in CNS and/or muscle and/or relative to the parent capsid or a reference capsid, such as AAV 8 or AAV 9 capsid, to reduce toxicity.
- a reference capsid for example, the parent capsid or an AAV8 or AAV9 capsid
- rAAVs with enhanced or increased biodistribution, including transduction, genome integration, transgene transcription and expression, in CNS tissues (including frontal cortex, hippocampus, cerebellum, midbrain) relative to a reference capsid (for example the unengineered, parental capsid that has been modified or AAV8 or AAV9), with reduced distribution, including transduction, genome integration, transgene transcription and expression in the liver and/or dorsal root ganglion cells (cervical, thoracic, and/or lumbar) compared to the biodistribution in CNS tissue and/or relative to an AAV with a reference capsid, such as the parental capsid or AAV8 or AAV9.
- rAAVs may be useful to deliver therapeutic proteins for the treatment of CNS disease.
- rAAVs with enhanced or increased biodistribution including transduction, genome integration, transgene transcription and expression, in skeletal muscle and/or cardiac muscle tissues relative to a reference capsid (for example the unengineered, parental capsid or AAV8 or AAV9), with reduced distribution, including transduction, genome integration, transgene transcription and expression in the liver and/or dorsal root ganglion cells (cervical, thoracic, and/or lumbar) compared to the biodistribution in muscle tissue and/or relative to an AAV with a reference capsid, such as the parental capsid or AAV8 or AAV9.
- a reference capsid for example the unengineered, parental capsid or AAV8 or AAV9
- Such rAAVs may be useful to deliver therapeutic proteins for the treatment of muscle disease.
- AAV9 capsid proteins or AAV8 capsid proteins SEQ ID NO:67 or 66, respectively, and as numbered in FIG.
- AAV9 capsid proteins or AAV8 capsid proteins SEQ ID NO:67 or 66, respectively, and as numbered in FIG.
- amino acid substitutions including, 2, 3 or 4 amino acid substitutions
- amino acid substitutions include S263F/S269T/A273T of AAV9, and corresponding substitutions in other AAV type capsids (for example according to the alignment in FIG.
- capsids particularly AAV9 capsids having a peptide TLAAPFK (SEQ ID NO:1) inserted between Q588 and A589 (herein PHP.hDYN) or alternatively between S268 and S269 or between S454 and G455) or inserted in another AAV capsid at a corresponding position (see, e.g., FIG. 7).
- the capsid is an AAV9 PHP.eB capsid (which has the modifications A587D and Q588G and insertion of the peptide TLAVPFK (SEQ ID NO:20) between G588 and A589) and the peptide TILSRSTQTG (SEQ ID NO: 15) between position 138 and 139, or the corresponding.
- Additional capsids have a Kidneyl peptide LPVAS inserted into the capsid, for example between S454 and G455 of AAV9, or alternatively between S268 and S269 or between Q588 and A589, or the corresponding position of a different capsid.
- the capsids can comprise R697W substitution of AAV rh64Rl .
- the capsids having these amino acid substitutions and insertions may further have substitutions of the NNN (asparagines) at 496 to 498 with AAA (alanines) of the AAV9 capsid or at positions 498 to 500 of the AAV8 capsid, or corresponding substitutions in other AAV type capsids.
- Engineered capsids include AAV8.BB.LD (A269S,498-NNN/AAA-500 substitutions in the amino acid sequence of AAV8, SEQ ID NO 66), AAV9.BB.LD (S263G/S269T/A273T, 496-NNN/AAA-498 substitutions in the amino acid sequence of AAV9, SEQ ID NO 67), AAV9.496-NNN/AAA-498 (SEQ ID NO: 31), AAV9.496- NNN/ AAA-498.
- W503R SEQ ID NO: 32
- AAV9.W503R SEQ ID NO: 33
- AAV9.Q474A SEQ ID NO: 34
- the capsid can be AAV9.N272A.496- NNN-498 (SEQ ID NO:91) or AAV9.G266A.496-NNN-498 (SEQ ID NO: 92).
- the capsid is not an engineered capsid, but is an AAVrh.10 capsid (SEQ ID NO: 69), an AAVrh.46 capsid (SEQ ID NO:93), an AAVrh.64.Rl capsid (SEQ ID NO: 90) or an AAVrh.73 capsid (SEQ ID NO: 88).
- transduction is measured by detection of transgene, such as GFP fluorescence.
- the capsid protein to be engineered may be an AAV9 capsid protein but may also be any AAV capsid protein, such as AAV serotype 1 (SEQ ID NO:59); AAV serotype 2 (SEQ ID NO:60); AAV serotype 3 (SEQ ID NO:61), AAV serotype 3B, AAV serotype 4 (SEQ ID NO:62); AAV serotype 5 (SEQ ID NO:63); AAV serotype 6 (SEQ ID NO:64); 451-461 of AAV7 capsid (SEQ ID NO:65); 451-461 of AAV8 capsid (SEQ ID NO:66); AAV serotype 9 (SEQ ID NO:67); AAV serotype 9e (SEQ ID NO:68); AAV serotype rhlO (SEQ ID NO:69); AAV serotype rh20 (SEQ ID NO:70); and AAV serotype hu.37 (SEQ ID NO:71), AAV serotype r
- the capsids of these vectors are not engineered.
- unmodified AAV serotype rh64Rl SEQ ID NOVO
- AAV serotype rh.10 ((SEQ ID NO: 69)
- AAV serotype rh46 (SEQ ID NO:93)
- AAV serotype rh73 (SEQ ID NO: 88) can be used in the disclosed methods and compositions.
- rAAVs incorporating the engineered capsids described herein including rAAVs with genomes comprising a transgene of therapeutic interest, including a transgene encoding a therapeutic protein for treatment of a muscle, heart or CNS disease.
- Packaging cells for producing the rAAVs described herein are provided.
- Method of treatment by delivery of, and pharmaceutical compositions comprising, the engineered rAAVs described herein are also provided. Also provided are methods of manufacturing the rAAVs with the engineered capsids described herein.
- the invention is illustrated by way of examples infra describing the construction of rAAV9 capsids engineered with amino acid substitutions and assaying of tissue distribution when administered to non-human primates.
- a recombinant AAV capsid protein comprising one or more amino acid substitutions relative to the wild type or unengineered capsid protein, in which the rAAV capsid protein is an AAV9 capsid protein (SEQ ID NO:67) with S263G/S269R/A273T substitutions, a G266A substitution, an N272A substitution, a W503R substitution, a Q474A substitution, 496-NNN/AAA-498 substitutions, has an insertion of the peptide TLAAPFK between Q588 and A589, S268 and S269, or S454 and G455, or is an AAV8 capsid (SEQ ID NO:6) with an A269S substitution or 498-NNN/AAA-500 substitutions, or corresponding substitutions or peptide insertions in a capsid protein of another AAV type capsid.
- the rAAV capsid protein is an AAV9 capsid protein (SEQ ID NO
- AAV capsid protein of embodiment 1 further comprising 498- NNN/ AAA-500 amino acid substitutions for an AAV8 capsid protein (SEQ ID NO: 66) or 496- NNN/AAA-498 amino acid substitutions for an AAV9 capsid protein (SEQ ID NO:67), or corresponding substitutions in a capsid protein of another AAV type capsid.
- AAV capsid protein of embodiments 1 or 2 which is an AAV8.BBB.LD capsid (SEQ ID NO: 27), an AAV9.BBB.LD capsid (SEQ ID NO: 29), an AAV9.496-NNN/AAA-498 capsid (SEQ ID NO: 31), AAV9.496-NNN/ AAA-498 capsid (SEQ ID NO: 32), AAV9.W503R capsid (SEQ ID NO: 33), AAV9.Q474A capsid (SEQ ID NO: 34), AAV9.N272A.496-NNN/AAA-498 capsid (SEQ ID NO: 91) or AAV9.N266A.496- NNN/ AAA-498 capsid (SEQ ID NO: 92).
- AAV9 capsid including an AABPHP.eB capsid, protein, or an AAV8 capsid.
- AAV type capsid is AAV rh.34, AAV4, AAV5, AAV hu.26, AAV rh.31, AAV hu.13, AAV hu.26, AAV hu.56, AAV hu.53, AAV7, AAV rh.10, AAV rh.64.Rl, AAV rh.46 or AAV rh.73.
- a nucleic acid comprising a nucleotide sequence encoding the rAAV capsid protein of any of embodiments 1 to 13, or encoding an amino acid sequence sharing at least 80% identity therewith and retaining the biological activity of the capsid.
- a packaging cell capable of expressing the nucleic acid of embodiment 14 or 15 to produce AAV vectors comprising the capsid protein encoded by said nucleotide sequence.
- a rAAV vector comprising the capsid protein of any of embodiments 1 to 13.
- the rAAV vector of embodiment 17 further comprising a transgene encoding a therapeutic protein operably linked to a regulatory sequence for expression in the muscle and/or CNS cells.
- a pharmaceutical composition comprising the rAAV vector of embodiment 17 or 18 and a pharmaceutically acceptable carrier.
- a method of delivering a transgene to a cell comprising contacting said cell with the rAAV vector of embodiment 17 or 18, wherein said transgene is delivered to said cell.
- a method of delivering a transgene to a target tissue of a subj ect in need thereof comprising administering to said subject the rAAV vector of embodiment 17 or 18, wherein the transgene is delivered to said target tissue.
- transgene is a muscle disease or heart disease therapeutic and said target tissue is cardiac muscle or skeletal muscle.
- a pharmaceutical composition for use in delivering a transgene to a cell comprising the rAAV vector of embodiment 17 or 18, wherein said transgene is delivered to said cell.
- a method of treating a CNS disorder in a subject in need thereof comprising administering a therapeutically effective amount of pharmaceutical composition of any of embodiments 27, 28, 32 to 37.
- a method of treating a muscle disorder in a subject in need thereof comprising administering a therapeutically effective amount of the pharmaceutical composition of any of embodiments 27-31 and 37.
- FIG. 1 depicts sequence comparison of the capsid amino acid sequences including the VR-IV loop of the adeno-associated virus type 9 (AAV9 VR-IV) from residues L447 to R476, (with residues 451-459 bracketed) to corresponding to regions of other AAVs.
- Figure discloses SEQ ID NOS:49-54, 50, and 55-58, respectively, in order of appearance.
- the top sequence is the consensus sequence, SEQ ID NO: 48.
- FIG. 2 depicts a protein model of an AAV capsid structure, showing capsid variable regions VR-IV, VR-V and VR-VIII.
- the box highlights the loop region of VR-IV which provides surface-exposed amino acids as represented in the model.
- FIG. 3 depicts high packaging efficiency (titer) in terms of genome copies per mL (GC/mL) of wild type AAV9 and eight (8) candidate modified rAAV9 vectors (1090, 1091, 1092, 1093, 1094, 1095, 1096, and 1097), where the candidate vectors each contain a FLAG insert immediately after different sites within AAV9s VR-IV, from residues 1451 to Q458, respectively. All vectors were packaged with luciferase transgene in 10 mL culture; error bars represent standard error of the mean.
- FIG. 4 demonstrates surface exposure of 1 VR-IV loop FLAG inserts in each of eight (8) candidate modified rAAV9 vectors (1090, 1091, 1092, 1093, 1094, 1095, 1096, and 1097), confirmed by immunoprecipitation of packaged vectors by binding to anti-FLAG resin.
- FIGs. 5A-5B depict transduction efficiency in Lec2 cells, transduced with capsid vectors carrying the luciferase gene (as a transgene), which were packaged into either wild type AAV9 (9-luc), or into each of eight (8) candidate modified (FLAG peptide inserted) rAAV9 vectors (1090, 1091, 1092, 1093, 1094, 1095, 1096, and 1097); transduction activity is expressed as percent luciferase activity, taking the activity of 9-luc as 100% (FIG. 5A), or as Relative Light Units (RLU) per microgram of protein (FIG. 5B).
- FIGs. 6A-6E FIG.
- FIG. 6A depicts a bar graph illustrating that insertions immediately after S454 of AAV9 of varying peptide length and composition may affect production efficiencies of AAV particles in a packaging cell.
- Ten peptides of varying composition and length were inserted after S454 within AAV9 VR-IV.
- qPCR was performed on harvested supernatant of transfected suspension HEK293 cells five days post-transfection.
- the results depicted in the bar graph demonstrate that the nature of the insertions affects the ability of AAV particles to be produced and secreted by HEK293 cells, and indicated by overall yields (titer). (Error bars represent standard error of the mean length of peptide, which is noted on the Y-axis in parenthesis.)
- 6B-6E depict fluorescence images of transduced cell cultures of the following cell lines: (6B) Lec2 cell line (6C) HT-22 cell line, (6D) hCMEC/D3 cell line, and (6E) C2C12 cell line.
- 6B Lec2 cell line
- 6C HT-22 cell line
- 6D hCMEC/D3 cell line
- 6E C2C12 cell line.
- AAV9 wild type and S454 insertion homing peptide capsids containing GFP transgene were used to transduce the noted cell lines.
- Pl vector was not included in images due to extremely low transduction efficiency, and P8 vector was not included due to low titer.
- AAV9.S454.FLAG showed low transduction levels in every cell type tested.
- FIG. 7 depicts alignment of AAVs l-9e, 3B, rhlO, rh20, rh39, rh73, rh74 version 1 and version 2, hul2, hu21, hu26, hu37, hu51 and hu53 capsid sequences with insertion sites for heterologous peptides after the initiation codon of VP2, and within or near variable region 1 (VR-I), variable region 4 (VR-IV), and variable region 8 (VR-VIII), all highlighted in grey; a particular insertion site within variable region eight (VR-VIII) of each capsid protein is shown by the symbol (after amino acid residue 588 according to the amino acid numbering of AAV9).
- FIG. 8 depicts copies of GFP (green fluorescent protein) transgene in mice brain cells, following administration of the AAV vectors: AAV9; AAV. PHP. eB, also referred to herein as AAV9e (AAV9 with the peptide TLAVPFK (SEQ ID NO:20) inserted between positions 588 and 589 and modifications A587D/A588G); AAV.hDyn (AAV9 with TLAAPFK (SEQ ID NO: 1) between 588 and 589); AAV.PHP.S (AAV9 with the peptide QAVRTSL (SEQ ID NO: 16) inserted between positions 588 and 589); and AAV. PHP. SH (AAV9 with the peptide QAVRTSH (SEQ ID NO: 17) inserted between positions 588 and 589).
- AAV9e AAV9 with the peptide TLAVPFK (SEQ ID NO:20) inserted between positions 588 and 589 and modifications A587D/A588G
- FIGs. 9A-9C depict the amino acid sequences for a recombinant AAV9 vector including a peptide insertion of TLAAPFK (SEQ ID NO:1) between Q588 and A589 (FIG. 9A), between S268 and S269 of VR-III (FIG. 9B), and between S454 and G455 of VR-IV (FIG. 9C), each with the TLAAPFK (SEQ ID NO: 1) insert shown in bold.
- FIGs. 10A-10B depict an in vitro transwell assay for AAV vectors crossing a blood brain barrier (BBB) cell layer (FIG.
- BBB blood brain barrier
- FIG. 11 depicts results of Next Generation Sequencing (NGS) analysis of brain gDNA from mice to which pools of engineered and native capsids have been intravenously administered, revealing relative abundances in tissues of the mice of the different capsids in the pool.
- NGS Next Generation Sequencing
- Three different pools were injected into mice. Dotted lines indicate which vectors were pooled together.
- Parental AAV9 was included in each pool as control (Pool 1 : BC01, Pool 2: BC31, Pool 3: BC01). Bar codes for each capsid of the pool are listed in Tables 6a-6c.
- FIGs. 12A-12H depict an in vivo transduction profile of AAV.hDyn in female C57B1/6 mice, showing copy number/microgram gDNA in naive mice, or mice injected with either AAV9 or AAV.hDyn in brain (FIG. 12A), liver (FIG. 12B), heart (FIG. 12C), lung (FIG. 12D), kidney (FIG. 12E), skeletal muscle (FIG. 12F), sciatic nerve (FIG. 12G), and ovary (FIG. 12H), where AAV.hDyn shows increased brain bio-distribution compared to AAV9.
- FIGs. 13A-13C depict distribution of GFP from AAV.hDyn throughout the brain, where images of immunohistochemical staining of brain sections from the striatum (FIG. 13A), hippocampus (FIG. 13B), and cortex (FIG. 13C) revealed a comprehensive transduction of the brain by the modified vector.
- FIG. 14 depicts in vivo kidney to liver transduction efficiency ratio of genetically engineered AAV9 vectors containing insertions of homing peptides immediately after amino acid 454. Details on peptides used in this study are outlined in Table 6.
- FIG. 15 depicts the relative abundance (RA) of the viral genomes (normalized to input) in the frontal cortex of the cynomolgus monkey model.
- FIGS. 16 and 17 depict the Relative Abundance of the viral genomes (normalized to input) in the hippocampus and the cerebellum of the cynomolgus monkey model, respectively.
- the RA of AAV.rh34 is shown by the shaded column on the left side of the graphs and the RA of AAV9 reference is showed by the shaded column in the middle of the graphs.
- FIGS. 16 and 17 show that AAV.rh34 is a top performing capsid in the intravenous administration pool.
- FIG. 18 depicts a Venn diagram of the: top 45 performers in FC (highest RA to AAV9), and bottom 45 performers in the cervical, thoracic, and lumbar DRGs (lowest RA to AAV9) and the AAVrh34 capsid is shown as the only capsid that was present in each group of 45 amongst the pool of capsids.
- FIG. 19 depicts the RA of the viral genomes (normalized to input and AAV9 control) in the frontal cortex of the cynomolgus monkey model.
- FIG. 20 depicts the RA of the viral genomes (normalized to input) in the hippocampus of the cynomolgus monkey model.
- FIG. 21 depicts the RA of the viral genomes (normalized to input) in the midbrain of the cynomolgus monkey model.
- FIG. 22 depicts the RA of the viral genomes (normalized to input) in the cerebellum of the cynomolgus monkey model.
- FIG. 23 depicts the RA of the viral genomes (normalized to input) in the cervical DRGs of the cynomolgus monkey model.
- FIG. 24 depicts the RA of the viral genomes (normalized to input) in the lumbar DRGs of the cynomolgus monkey model.
- FIG. 25 depicts a Venn diagram of the top performing 15 capsids transducing the frontal cortex, hippocampus, midbrain and cerebellum following ICV administration. As indicated in the diagram, AAV6, AAV8.BBB, AAV.rh.46, and AAV1 were the only AAVs represented in each of the top performing groups.
- FIG. 26 depicts a Venn diagram of the top performing 45 capsids transducing the hippocampus and the 45 capsids with the lowest transduction values for DRG, to identify hippocampus-targeting DRG friendly capsids.
- AAV.hu.60, AAV.rh.21, AAV.PHP.hB, AAV.rh.15, AAV.rh.24, AAV9.W503R, hu.5, AAV9.Q474A, and AAV.hu.10 were the only AAVs represented in each of the groups.
- FIG. 27 depicts a Venn diagram of the top performing 40 capsids transducing the heart, biceps, and gastrocnemius and the 40 capsids with the lowest transduction values for the liver, to identify muscle-targeting capsids that have reduced targeting to the liver.
- AAV.PHPeB.VP2Herp was the only AAVs represented in each of the groups.
- FIG. 28 depicts a Venn diagram of the top performing 15 capsids transducing the heart, biceps, and gastrocnemius muscle.
- FIGS. 29A and B depict the RA of the viral genomes (normalized to input) in the gastrocnemius and the liver of the cynomolgus monkey model, respectively.
- FIG. 30A and 30B depict the number of genome copies of DNA (A) or RNA (B) of select “liver-detargeting” (LD) vectors as detected in the liver of NHPs following IV administration of the capsid library.
- FIG. 31 depicts the biodistribution of select “liver-detargeting” (LD) vectors compared to their parental AAV9 capsid in various tissues, in NHPs following IV administration of the capsid library.
- LD liver-detargeting
- FIG. 32 depicts the biodistribution of select LD vectors compared to their parental AAV8 capsid in various tissues, in NHPs following IV administration of the capsid library.
- FIGs 33 A and 33B depict the change in relative abundance for point mutations affecting AAV9 transduction (or liver transduction) as compared to AAV9.
- the four mutants depicted in this study demonstrate retention in the blood when compared to wild-type AAV9.
- FIG 33B shows the change in relative abundance for the AAV8 and AAV9 mutants combining the NNN/AAA mutation with the transport motif BBB (A269S, in AAV8; S263G/S269T/A273T, in AAV9), as compared to parental capsid (AAV8 or AAV9, respectively).
- FIG. 34A and FIG. 34B show the increase in blood retention 3-24 hr relative to AAV9.
- FIG. 34B shows the increase in blood retention 3-24 hr relative to parental AAV.
- FIG. 35 depicts the biodistribution of select AAV vectors in muscle tissues, including cardiac muscle, as well as cerebrum, liver and pancreas in wild-type B6 mice following IV administration of the capsid library.
- FIGs. 36A-36H depicts biodistribution of various capsids in wild-type B6 mice compared to that of mdx mouse tissue.
- rAAVs recombinant adeno-associated viruses
- the rAAV has enhance desired properties, such as increased tissue targeting, including transduction, genome integration and transgene expression, particularly, preferentially, relative to the reference capsid protein (e.g., the unengineered or wild type capsid), to CNS or to heart and/or skeletal muscle tissue.
- the engineered capsid has reduced tropism (i.e., tissue targeting, transduction and integration of the rAAV genome) relative to the reference capsid for liver, dorsal root ganglion and/or peripheral nervous tissue to reduce toxicity of the AAV gene therapy.
- the modifi cations include amino acid substitutions (including 1, 2, 3, 4, 5, 6, 7 or 8 amino acid substitutions) and/or peptide insertions (4 to 20, or 7 contiguous amino acids, and in embodiments no more than 12 contiguous amino acids from a heterologous protein) as described herein.
- the AAV capsid protein to be engineered is, in certain embodiments, an AAV9 capsid protein or an AAV8 capsid protein.
- the AAV capsid to be engineered is an AAV rh.34, AAV4, AAV5, AAV hu.26, AAV rh.31, AAV hu.13, AAV hu.56, AAV hu.53, AAV7, AAV rh64Rl, AAV rh46 or AAV rh73 capsid protein. (See FIG. 7 and Table 17 for sequences)
- engineered capsids having one or more amino acid substitutions that promote transduction and/or tissue tropism, particularly for enhanced, relative to an unengineered capsid, targeting for heart and/or skeletal muscle and, in embodiments, reduced, relative to an unengineered capsid, targeting for liver, dorsal root ganglion, and/or peripheral nervous tissue.
- the amino acid substitutions are S263F/S269T/A273T of AAV9, and corresponding substitutions in other AAV type capsids (for example according to the alignment in FIG.
- capsids particularly AAV9 capsids having a peptide TLAAPFK (SEQ ID NO: 1) inserted between Q588 and A589 (herein PHP.hDYN) or alternatively between S268 and S269 or between S454 and G455) or inserted in another AAV capsid at a corresponding position (see, e.g., FIG. 7).
- the capsid is an AAV9 PHP.eB capsid (which has the modifications A587D and Q588G and insertion of the peptide TLAVPFK (SEQ ID NO:20) between G588 and A589) and the peptide TILSRSTQTG (SEQ ID NO: 15) between position 138 and 139, or the corresponding.
- Additional capsids have a Kidneyl peptide LPVAS inserted into the capsid, for example between S454 and G455 of AAV9, or alternatively between S268 and S269 or between Q588 and A589, or the corresponding position of a different capsid.
- the capsids can comprise R697W substitution of AAV rh64Rl.
- the capsids having these amino acid substitutions and insertions may further have substitutions of the NNN (asparagines) at 496 to 498 with AAA (alanines) of the AAV9 capsid or at positions 498 to 500 of the AAV8 capsid, or corresponding substitutions in other AAV type capsids.
- Engineered capsids include AAV8.BB.LD (A269S,498- NNN/ AAA-500 substitutions in the amino acid sequence of AAV8, SEQ ID NO 66), AAV9.BB.LD (S263G/S269T/A273T, 496-NNN/AAA-498 substitutions in the amino acid sequence of AAV9, SEQ ID NO 67), AAV9.496-NNN/AAA-498 (SEQ ID NO: 31), AAV9.496-NNN/AAA-498.W503R (SEQ ID NO: 32), AAV9.W503R (SEQ ID NO: 33), or AAV9.Q474A (SEQ ID NO: 34).
- the capsid can be AAV9.N272A.496- NNN-498 (SEQ ID NO:91) or AAV9.G266A.496-NNN-498 (SEQ ID NO: 92).
- the capsid is not an engineered capsid, but is an AAVrh.10 capsid (SEQ ID NO: 69), an AAVrh.46 capsid (SEQ ID NO:93), an AAVrh.64.Rl capsid (SEQ ID NO: 90) or an AAVrh.73 capsid (SEQ ID NO: 88).
- transduction is measured by detection of transgene, such as GFP fluorescence.
- the capsids having these amino acid substitutions and insertions may further have substitutions of the NNN (asparagines) at 496 to 498 with AAA (alanines) of the AAV9 capsid, or corresponding substitutions in other AAV type capsids.
- This engineered capsid may exhibit preferential targeting for heart and/or skeletal muscle, and reduced targeting (compared to an AAV bearing the unengineered capsid) for liver and/or dorsal root ganglion cells and/or peripheral nervous system tissue, and may particularly useful for delivery of a transgene encoding a therapeutic protein for treatment of a muscle disease.
- a recombinant capsid protein including an engineered AAV9 capsid protein, and an rAAV comprising the capsid protein, in which the peptide TLAVPFK (SEQ ID NO:20) is inserted between G588 and A589 of AAV9, and, in particular, the capsid protein also has amino acid substitutions A587D/Q588G (PHP.eB) and further has the peptide TILSRSTQTG (SEQ ID NO: 15) inserted after position 138 of AAV9 (collectively, AAVPHPeB.VP2Herp; see Table 17), or in the corresponding positions of another AAV.
- Kidneyl peptide LPVAS (SEQ ID NO:6) (or alternatively CLPVASC (SEQ ID NO:5)) inserted into the capsid, for example between S454 and G455 of AAV9 (see Table 17), or alternatively between S268 and S269 or between Q588 and A589, or the corresponding position of a different capsid.
- Such an engineered capsid may exhibit preferential targeting for heart and skeletal muscle, and reduced targeting (as compared to an AAV having the unengineered capsid) for liver and/or dorsal root ganglion cells and may particularly useful for delivery of a transgene encoding a therapeutic protein for treatment of a muscle disease (such as, but not limited to a muscular dystrophy).
- the engineered rAAV exhibits at least 1.1-fold, 1.5-fold, 2-fold, 3- fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold greater transduction in cardiac muscle and/or skeletal muscle cells compared to a reference AAV capsid, including an AAV9 capsid or an AAV8 capsid, or the parental capsid.
- the muscle is gastrocnemius muscle, bicep, tricep and/or heart muscle.
- the engineered rAAV exhibits of 50%, 60%, 70%, 80%, 90%, 95% or 99% less transduction in liver compared to the reference AAV capsid compared to a reference AAV capsid, including an AAV 9 capsid or an AAV 8 capsid, or the parental capsid.
- the rAAV exhibits of 50%, 60%, 70%, 80%, 90%, 95% or 99% less transduction in dorsal root ganglion cells (including in cervical, thoracic or lumbar DRG cells) compared to the reference AAV capsid.
- the enhanced and/or reduce transduction may be with any mode of administration, by intravenous administration, intramuscular administration, or any type of systemic administration, intrathecal administration or ICV administration.
- engineered capsids having one or more amino acid substitutions that promote transduction and/or tissue tropism, particularly for enhanced, relative to an unengineered capsid, targeting for CNS and, in embodiments, reduced, relative to an unengineered capsid, targeting for liver, dorsal root ganglion, and/or peripheral nervous tissue.
- the amino acid substitutions areA269S of AAV8 (or at a corresponding position in a different AAV serotype capsid), S263G/S269T/A273T of AAV9 (or at a corresponding position in a different AAV serotype capsid), N272A or N266A of AAV9 (or at a corresponding position in a different AAV serotype capsid), Q474A of AAV9 (or at a corresponding position in a different AAV serotype capsid), or W503R of AAV9 (or at a corresponding position in a different AAV serotype capsid), or R697W of rh64Rl (or at a corresponding position in a different AAV serotype capsid).
- the capsids having these amino acid substitutions and insertions may further have or alternatively have substitutions of the NNN (asparagines) at 496 to 498 with AAA (alanines) of the AAV9 capsid (SEQ ID NO: 67) or have substitutions of the NNN (asparagines) at 498 to 4500 with AAA (alanines) of the AAV8 capsid (SEQ ID NO: 66), or corresponding substitutions in other AAV type capsids.
- This engineered capsid may exhibit preferential targeting for CNS, and reduced targeting (compared to an AAV bearing the unengineered capsid) for liver and/or dorsal root ganglion cells and/or peripheral nervous system tissue, and may particularly useful for delivery of a transgene encoding a therapeutic protein for treatment of a CNS disease.
- capsid proteins and rAAVs comprising them, that have inserted peptides that target and/or promote rAAV cellular uptake, transduction and/or genome integration in CNS tissue and, in embodiments, reduced, relative to an unengineered capsid, targeting for liver, dorsal root ganglion, and/or peripheral nervous tissue, for example, the peptide TILSRSTQTG (SEQ ID NO: 15); TLAVPFK (SEQ ID NO:20); or TLAAPFK (SEQ ID NO: 1).
- the peptide TLAAPFK (SEQ ID NO: 1) is inserted between Q588 and A589 of AAV9 (AAV9.hDyn; see Table 17), or the corresponding position of another AAV (see FIG. 7).
- the capsid is rh.34, rh.10, rh.46, rh.73, or rh64.Rl (Fig. 7 or Table 17 for sequence), or an engineered form of rh.34, rh.10, rh.46, rh.73, or rh64.Rl.
- engineered capsids may exhibit preferential targeting for CNS, and reduced targeting (compared to an AAV bearing the unengineered capsid) for liver and/or dorsal root ganglion cells and/or peripheral nervous system tissue, and may particularly useful for delivery of a transgene encoding a therapeutic protein for treatment of a CNS disease.
- the engineered rAAV exhibits at least 1.1-fold, 1.5-fold, 2-fold, 3- fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold greater transduction in CNS tissue compared to a reference AAV capsid, such as the parental capsid or AAV8 or AAV9.
- the CNS tissue may be one or more of the frontal cortex, hippocampus, cerebellum, midbrain and/or hindbrain.
- the engineered rAAV exhibits of 50%, 60%, 70%, 80%, 90%, 95% or 99% less transduction in liver compared to the reference AAV capsid such as the parental capsid or AAV8 or AAV9.
- the rAAV exhibits of 50%, 60%, 70%, 80%, 90%, 95% or 99% less transduction in dorsal root ganglion cells (including in cervical, thoracic or lumbar DRG cells) compared to the reference AAV capsid such as the parental capsid or AAV8 or AAV9.
- the enhanced and/or reduce transduction may be with any mode of administration, by intravenous administration, intramuscular administration, or any type of systemic administration, intrathecal administration or ICV administration.
- Recombinant vectors comprising the capsid proteins also are provided, along with pharmaceutical compositions thereof, nucleic acids encoding the capsid proteins, and methods of making and using the capsid proteins and rAAV vectors having the engineered capsids for targeted delivery, improved transduction and/or treatment of disorders associated with the target tissue.
- AAV “serotype” refers to an AAV having an immunologically distinct capsid, a naturally-occurring capsid, or an engineered capsid.
- AAV or “adeno-associated virus” refers to a Dependoparvovirus within the Parvoviridae genus of viruses.
- the AAV can be an AAV derived from a naturally occurring “wild-type” virus, an AAV derived from a rAAV genome packaged into a capsid comprising capsid proteins encoded by a naturally occurring cap gene and/or from a rAAV genome packaged into a capsid comprising capsid proteins encoded by a non-naturally occurring capsid cap gene.
- An example of the latter includes a rAAV having a capsid protein comprising a peptide insertion into the amino acid sequence of the naturally-occurring capsid.
- rAAV refers to a “recombinant AAV.”
- a recombinant AAV has an AAV genome in which part or all of the rep and cap genes have been replaced with heterologous sequences.
- rep-cap helper plasmid refers to a plasmid that provides the viral rep and cap gene function and aids the production of AAVs from rAAV genomes lacking functional rep and/or the cap gene sequences.
- capsid protein refers to the nucleic acid sequences that encode capsid proteins that form or help form the capsid coat of the virus.
- the capsid protein may be VP1, VP2, or VP3.
- replica gene refers to the nucleic acid sequences that encode the non- structural protein needed for replication and production of virus.
- nucleic acids and “nucleotide sequences” include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules e.g., mRNA), combinations of DNA and RNA molecules or hybrid DNA/RNA molecules, and analogs of DNA or RNA molecules.
- Such analogs can be generated using, for example, nucleotide analogs, which include, but are not limited to, inosine or tritylated bases.
- Such analogs can also comprise DNA or RNA molecules comprising modified backbones that lend beneficial attributes to the molecules such as, for example, nuclease resistance or an increased ability to cross cellular membranes.
- the nucleic acids or nucleotide sequences can be single-stranded, doublestranded, may contain both single-stranded and double-stranded portions, and may contain triple-stranded portions, but preferably is double-stranded DNA.
- a subject is a mammal such as a non-primate (e.g., cows, pigs, horses, cats, dogs, rats etc.) or a primate (e.g., monkey and human), or, in certain embodiments, a human.
- a non-primate e.g., cows, pigs, horses, cats, dogs, rats etc.
- a primate e.g., monkey and human
- a “therapeutic agent” refers to any agent which can be used in treating, managing, or ameliorating symptoms associated with a disease or disorder, where the disease or disorder is associated with a function to be provided by a transgene.
- a “therapeutically effective amount” refers to the amount of agent, (e.g., an amount of product expressed by the transgene) that provides at least one therapeutic benefit in the treatment or management of the target disease or disorder, when administered to a subject suffering therefrom.
- a therapeutically effective amount with respect to an agent of the invention means that amount of agent alone, or when in combination with other therapies, that provides at least one therapeutic benefit in the treatment or management of the disease or disorder.
- prophylactic agent refers to any agent which can be used in the prevention, delay, or slowing down of the progression of a disease or disorder, where the disease or disorder is associated with a function to be provided by a transgene.
- a “prophylactically effective amount” refers to the amount of the prophylactic agent (e.g., an amount of product expressed by the transgene) that provides at least one prophylactic benefit in the prevention or delay of the target disease or disorder, when administered to a subject predisposed thereto.
- a prophylactically effective amount also may refer to the amount of agent sufficient to prevent or delay the occurrence of the target disease or disorder; or slow the progression of the target disease or disorder; the amount sufficient to delay or minimize the onset of the target disease or disorder; or the amount sufficient to prevent or delay the recurrence or spread thereof.
- a prophylactically effective amount also may refer to the amount of agent sufficient to prevent or delay the exacerbation of symptoms of a target disease or disorder.
- a prophylactically effective amount with respect to a prophylactic agent of the invention means that amount of prophylactic agent alone, or when in combination with other agents, that provides at least one prophylactic benefit in the prevention or delay of the disease or disorder.
- a prophylactic agent of the invention can be administered to a subject “pre-disposed” to a target disease or disorder.
- a subject that is “pre-disposed” to a disease or disorder is one that shows symptoms associated with the development of the disease or disorder, or that has a genetic makeup, environmental exposure, or other risk factor for such a disease or disorder, but where the symptoms are not yet at the level to be diagnosed as the disease or disorder.
- a patient with a family history of a disease associated with a missing gene may qualify as one predisposed thereto.
- a patient with a dormant tumor that persists after removal of a primary tumor may qualify as one predisposed to recurrence of a tumor.
- the “central nervous system” refers to neural tissue reaches by a circulating agent after crossing a blood-brain barrier, and includes, for example, the brain, optic nerves, cranial nerves, and spinal cord.
- the CNS also includes the cerebrospinal fluid, which fills the central canal of the spinal cord as well as the ventricles of the brain. 5.2. Recombinant AAV Capsids and Vectors
- rAAVs recombinant adeno-associated viruses
- the rAAV has enhance desired properties, such as increased tissue targeting, including transduction, genome integration and transgene expression, particularly, preferentially, relative to the reference capsid protein (e.g., the unengineered or wild type capsid), to CNS or to heart and/or skeletal muscle tissue.
- the engineered capsid has reduced tropism (i.e., tissue targeting, transduction and integration of the rAAV genome) relative to the reference capsid for liver, dorsal root ganglion and/or peripheral nervous tissue to reduce toxicity of the AAV gene therapy.
- the modifications include amino acid substitutions (including 1, 2, 3, 4, 5, 6, 7 or 8 amino acid substitutions) and/or peptide insertions (4 to 20, or 7 contiguous amino acids, and in embodiments no more than 12 contiguous amino acids from a heterologous protein) as described herein.
- AAV capsids were modified by introducing selected single to multiple amino acid substitutions which increase effective gene delivery to the CNS or to cardiac or skeletal muscle, detarget the liver and/or dorsal root ganglion to reduce toxicity, and/or reduce immune responses of neutralizing antibodies.
- the capsids have one or more amino acid substitutions including a W503R substitution, a Q474 substitutional a N272A or N266A substitution in AAV9 or the corresponding substitution in another AAV serotype or an A269S substitution in AAV8 or the corresponding substitution in another AAV serotype.
- rAAV having a capsid with the Q474A substitution may be particularly useful for delivery to skeletal and/or cardiac muscle or CNS tissue and rAAV having a capsid with the W503R substitution may be particularly useful for delivery to CNS tissue, particularly with reduced, compared to reference capsid containing rAAVs, transduction in the liver and/or DRGs.
- substitutions include S263G/S269R/A273T substitutions in AAV9 or A587D/Q588G in AAV9 or corresponding substitutions in other AAV serotypes.
- the rAAV capsid can have a R697W substitution.
- the capsids having these amino acid substitutions and insertions may further have substitutions of the NNN (asparagines) at 496 to 498 with AAA (alanines) of the AAV9 capsid, or of the NNN (asparagines) at 498 to 500 with AAA (alanines) of the AAV8 capsid corresponding substitutions in other AAV type capsids.
- AAV serotypes that may be used for the amino acid substitutions and that may be the reference capsid include AAV8, AAV rh.34, AAV4, AAV5, AAV hu.26, AAV rh.31, AAV hu.13, AAV hu.26, AAV hu.56, AAV hu.53, AAV7, rh64Rl, rh46 or rh73.
- the capsid is rh34, either unmodified or serving as the parental capsid to be modified as detailed herein.
- capsids having one or more amino acid substitutions that promote transduction and/or tissue tropism of the rAAV having the modified capsid are provided.
- capsids having a single mutation at amino acid 269 of the AAV8 capsid replacing alanine with serine (A269S) are provided.
- capsids having multiple substitutions at amino acids 263, 269, and 273 of the AAV9 capsid resulting in the following substitutions: S263G, S269T, and A273T (herein referred to as AAV9.BBB) or substitutions corresponding to these positions in other AAV types.
- Exposure to the AAV capsid can generate an immune response of neutralizing antibodies.
- One approach to overcome this response is to map the AAV-specific neutralizing epitopes and rationally design an AAV capsid able to evade neutralization.
- a monoclonal antibody, specific for intact AAV9 capsids, with high neutralizing titer has recently been described (Giles et al, 2018, Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors).
- the epitope was mapped to the 3-fold axis of symmetry on the capsid, specifically to residues 496-NNN-498 and 588- QAQAQT-592 of AAV9 (SEQ ID NO:8).
- Capsid mutagenesis demonstrated that single amino acid substitution within this epitope markedly reduced binding and neutralization.
- mutations in the epitope conferred a “liver-detargeting” phenotype to the mutant vectors, suggesting that the same residues are also responsible for AAV9 tropism.
- Liver detargeting has also been associated with substitution of amino acid 503 replacing tryptophan with arginine. Presence of the W503R mutation in the AAV9 capsid was associated with low glycan binding avidity (Shen et al, 2012, Glycan Binding Avidity Determines the Systemic Fate of Adeno-Associated Virus Type 9).
- AAV8.BBB.LD AAV8.BBB.LD
- AAV9.BBB.LD AAV9.BBB.LD
- the AAVrhlO capsid was modified by substituting three asparagines at amino acid positions 498,
- capsids having three asparagines at amino acid positions 496, 497, and 498 of the AAV9 capsid replaced with alanines and also tryptophan at amino acid 503 of the AAV9 capsid with arginine or capsids with substitutions corresponding to these positions in other AAV types.
- the capsid is an AAV8.BB.LD capsid (A269S,498- NNN/ AAA-500 substitutions in the amino acid sequence of AAV8, SEQ ID NO 66), an AAV9.BBB.LD capsid (S263G/S269T/A273T, 496-NNN/AAA-498 substitutions in the amino acid sequence of AAV9, SEQ ID NO 67), an AAV9.496-NNN/AAA-498 capsid (SEQ ID NO: 31), an AAV9.496-NNN/AAA-498.W503R capsid (SEQ ID NO: 32), an AAV9.W503R capsid (SEQ ID NO: 33), or an AAV9.Q474A capsid (SEQ ID NO: 34).
- AAV8.BB.LD capsid A269S,498- NNN/ AAA-500 substitutions in the amino acid sequence of AAV8, SEQ ID NO 66
- the capsid can be an AAV9.N272A.496-NNN-498 capsid (SEQ ID NO:91) or an AAV9.G266A.496-NNN-498 capsid (SEQ ID NO: 92).
- the rAAVs described herein increase tissue-specific (such as, but not limited to, CNS or skeletal and/or cardiac muscle) cell transduction in a subject (a human, non-human-primate, or mouse subject) or in cell culture, compared to the rAAV not comprising the amino acid substitution.
- the increase in tissue specific cell transduction is at least 2, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 fold more than that without the modification.
- the increase in transduction may be assessed using methods described in the Examples herein and known in the art.
- the rAAVs described herein increase the incorporation of rAAV genomes into a cell or tissue type in a subject (a human, non-human primate or mouse subject) or in cell culture to the rAAV not comprising the peptide insertion.
- the increase in genome integration is at least 2, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 fold more than an AAV having a capsid without the modification (i.e., the parental capsid).
- rAAVs having capsid proteins with one or more (generally one or two) peptide insertions wherein the peptide insertion increase effective gene delivery to the CNS or to cardiac or skeletal muscle and to detarget the liver and/or dorsal root ganglion to reduce toxicity relative to the parental capsid protein.
- the peptides include TLAVPFK, TLAAPFK, or TILSRSTQTG (or an at least 4, 5, 6, 7 amino acid portion thereof).
- the peptides may be inserted into the AAV9 capsid, for example after the positions 138; 262- 273; 452-461; 585-593 of AAV9 cap, particularly after position 138, 454 or 588 of AAV9 or a corresponding position in another AAV as detailed herein.
- the capsid has the peptide TLAVPFK (SEQ ID NO:20) is inserted between G588 and A589 of AAV9, and, in particular, the capsid protein also has amino acid substitutions A587D/Q588G (PHP.eB) and further has the peptide TILSRSTQTG (SEQ ID NO: 15) inserted after position 138 of AAV9 (collectively, AAVPHPeB.VP2Herp; see Table 17), or in the corresponding positions of another AAV.
- Additional capsids have a Kidneyl peptide LPVAS inserted into the capsid, for example between 454 and 455 of AAV9 (see Table 17), or alternatively or alternatively between S268 and S269 or between Q588 and A589 of AAV9 or the corresponding position of another AAV serotype.
- Such an engineered capsid may exhibit preferential targeting for heart and skeletal muscle, and reduced targeting (as compared to an AAV having the unengineered capsid) for liver and/or dorsal root ganglion cells and may particularly useful for delivery of a transgene encoding a therapeutic protein for treatment of a muscle disease (such as, but not limited to a muscular dystrophy).
- the peptide insertion comprises at least 4, 5, 6, 7, 8, 9, or all 10 consecutive amino acids of sequence TILSRSTQTG (SEQ ID NO: 15), preferably which contains the TQT or STQT (SEQ ID NO:9) motif. In some embodiments, the peptide insertion consists of at least 4, 5, 6, 7, 8, 9, or all 10 consecutive amino acids of sequence TILSRSTQTG (SEQ ID NO: 15), preferably which contains the TQT or STQT (SEQ ID NO:9) motif.
- the peptide insertion may be a sequence of consecutive amino acids from a domain that targets kidney tissue, or a conformation analog designed to mimic the three-dimensional structure of said domain.
- the kidneyhoming domain comprises the sequence CLPVASC (SEQ ID NO: 5) (see, e.g., US 5,622,699).
- the peptide insertion from said kidney-homing domain comprises at least 4, 5, 6, or all 7 amino acids from sequence CLPVASC (SEQ ID NO:5).
- the peptide insertion comprises or consists of the sequence CLPVASC (SEQ ID NO:5).
- a peptide having the sequence LPVAS also can be a kidney-homing peptide.
- Methods for determining the necessity of a cysteine residue or of amino acid residues N-terminal or C-terminal to a cysteine residue for organ homing activity of a peptide are routine and well known in the art.
- the peptide insertion comprises at least 4 or all 5 amino acids from sequence LPVAS (SEQ ID NO:6).
- the peptide insertion comprises or consists of the sequence LPVAS (SEQ ID NO:6).
- rAAVs having a capsid that has the peptide TLAAPFK (SEQ ID NO:1) is inserted between Q588 and A589 of AAV9 (AAV9.hDyn; see Table 17), or the corresponding position of another AAV (see, e.g., FIG. 7).
- Such an engineered capsid may exhibit preferential targeting for CNS tissue, and reduced targeting (as compared to an AAV having the unengineered capsid) for liver and/or dorsal root ganglion cells and may particularly useful for delivery of a transgene encoding a therapeutic protein for treatment of a CNS disease.
- capsids with peptide insertions at positions amenable to peptide insertions within and near the AAV9 capsid VR-IV loop (see FIG. 2) and corresponding regions on the VR-IV loop of capsids of other AAV types.
- the rAAV capsid protein comprises a peptide insertion immediately after (i.e., connected by a peptide bond C- terminal to) an amino acid residue corresponding to one of amino acids 451 to 461 of AAV9 capsid protein (amino acid sequence SEQ ID NO:67 and see FIG.
- capsid protein amino acid sequence of other AAV serotypes with amino acid sequence of the AAV9 capsid and Table 17 for other capsid sequences
- said peptide insertion is surface exposed when the capsid protein is packaged as an AAV particle.
- the peptide insertion should not delete any residues of the AAV capsid protein.
- the peptide insertion occurs in a variable (poorly conserved) region of the capsid protein, compared with other serotypes, and in a surface exposed loop.
- a peptide insertion described as inserted “at” a given site refers to insertion immediately after, that is having a peptide bond to the carboxy group of, the residue normally found at that site in the wild type virus.
- insertion at Q588 in AAV9 means that the peptide insertion appears between Q588 and the consecutive amino acid (A589) in the AAV9 wildtype capsid protein sequence (SEQ ID NO:67).
- the capsid protein is an AAV9 capsid protein and the insertion occurs immediately after at least one of the amino acid residues 451 to 461.
- the peptide insertion occurs immediately after amino acid 1451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460, or L461 of the AAV9 capsid (amino acid sequence SEQ ID NO:67).
- the peptide is inserted between residues S454 and G455 of AAV9 capsid protein or between the residues corresponding to S454 and G455 of an AAV capsid protein other than an AAV9 capsid protein (amino acid sequence SEQ ID NO: 67).
- engineered capsid proteins comprising targeting peptides heterologous to the capsid protein that are inserted into the AAV capsid protein such that, when incorporated into the AAV vector the heterologous peptide is surface exposed.
- the capsid protein is from at least one AAV type selected from AAV serotype 1 (AAV1), serotype 2 (AAV2), serotype 3 (AAV3), serotype 4 (AAV4), serotype 5 (AAV5), serotype 6 (AAV 6), serotype 7 (AAV7), serotype 8 (AAV8), serotype rh8 (AAVrh8), serotype 9e (AAV9e), serotype rhlO (AAVrhlO), serotype rh20 (AAVrh20), serotype rh39 (AAVrh39), serotype hu.37 (AAVhu.37), serotype rh74 (AAVrh74, versions 1 and 2), serotype rh34 (AAVrh34), serotype hu26 (AAVhu26), serotype rh31 (AAVrh31), serotype hu56 (AAVh
- the peptide insertion occurs immediately after one of the amino acid residues within: 450-459 of AAV1 capsid (SEQ ID NO:59); 449-458 of AAV2 capsid (SEQ ID NO:60); 449-459 of AAV3 capsid (SEQ ID NO:61); 443-453 of AAV4 capsid (SEQ ID NO:62); 442-445 of AAV5 capsid (SEQ ID NO:63); 450-459 of AAV6 capsid (SEQ ID NO:64); 451-461 of AAV7 capsid (SEQ ID NO:65); 451-461 of AAV8 capsid (SEQ ID NO:66); 451-461 of AAV9 capsid (SEQ ID NO:67); 452-461 of AAV9e capsid (SEQ ID NO:68); 452-461 of AAVrhlO capsid (SEQ ID NO: 69); 452-461 of AAVrh20 capsid (SEQ ID NO: 70); 452-461
- the rAAV capsid protein comprises a peptide insertion immediately after (i.e., C-terminal to) amino acid 588 of AAV9 capsid protein (having the amino acid sequence of SEQ ID NO: 67 and see FIG. 7), where said peptide insertion is surface exposed when the capsid protein is packaged as an AAV particle.
- the rAAV capsid protein has a peptide insertion that is not immediately after amino acid 588 of AAV9 or corresponding to amino acid 588 of AAV9.
- the peptide is inserted after 138; 262-272; 450-459; or 585- 593 of AAV1 capsid (SEQ ID NO:59); 138; 262-272; 449-458; or 584-592 of AAV2 capsid (SEQ ID NO:60); 138; 262-272; 449-459; or 585-593 of AAV3 capsid (SEQ ID NO:61); 137; 256-262; 443-453; or 583-591 of AAV4 capsid (SEQ ID NO:62); 137; 252-262; 442-445; or 574-582 of AAV5 capsid (SEQ ID NO:63); 138; 262-272; 450-459; 585-593 of AAV6 capsid (SEQ ID NO:64); 138; 263-273; 451-461; 586-594 of AAV7 capsid (SEQ ID NO:65); 138; 263-274; 452-461; 587-595 of A
- the peptide insertion is sequence of contiguous amino acids from a heterologous protein or domain thereof.
- the peptide to be inserted typically is long enough to retain a particular biological function, characteristic, or feature of the protein or domain from which it is derived.
- the peptide to be inserted typically is short enough to allow the capsid protein to form a coat, similarly or substantially similarly to the native capsid protein without the insertion.
- the peptide insertion is from about 4 to about 30 amino acid residues in length, about 4 to about 20, about 4 to about 15, about 5 to about 10, or about 7 amino acids in length.
- the peptide sequences for insertion are at least 4 amino acids in length and may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in length. In some embodiments, the peptide sequences are 16, 17, 18, 19, or 20 amino acids in length. In embodiments, the peptide is no more than 7 amino acids, 10 amino acids or 12 amino acids in length.
- a “peptide insertion from a heterologous protein” in an AAV capsid protein refers to an amino acid sequence that has been introduced into the capsid protein and that is not native to any AAV serotype capsid.
- Non-limiting examples include a peptide of a human protein in an AAV capsid protein.
- the rAAVs described herein increase tissue-specific (such as, but not limited to, CNS or skeletal and/or cardiac muscle) cell transduction in a subject (a human, non-human-primate, or mouse subject) or in cell culture, compared to the rAAV not comprising the amino acid substitution.
- the increase in tissue specific cell transduction is at least 2, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 fold more than that without the peptide insertion.
- the rAAVs described herein increase the incorporation of rAAV genomes into a cell or tissue type, particularly CNS or heart and/or skeletal muscle in a subject (a human, non-human primate or mouse subject) or in cell culture to the rAAV not comprising the peptide insertion.
- the increase in genome integration is at least 2, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 fold more than an AAV having a capsid without the peptide insertion.
- a heterologous peptide insertion library refers to a collection of rAAV vectors that carry the same peptide insertion at different insertion sites in the virus capsid, e.g., at different positions within a given variable region of the capsid or different variant peptides or even one or more amino acid substitutions.
- the capsid proteins used comprise AAV genomes that contain modified rep and cap sequences to prevent the replication of the virus under conditions in which it could normally replicate (co-infection of a mammalian cell along with a helper virus such as adenovirus).
- the members of the peptide insertion libraries may then be assayed for functional display of the peptide on the rAAV surface, tissue targeting and/or gene transduction.
- AAV1 138; 262-272; 450-459; 595-593; and in a particular embodiment, between 453- 454 (SEQ ID NO:59).
- AAV2 138; 262-272; 449-458; 584-592; and in particular embodiment, between 452- 453 (SEQ ID NO:60).
- AAV3 138; 262-272; 449-459; 585-593; and in particular embodiment, between 452- 453 (SEQ ID NO:61).
- AAV4 137; 256-262; 443-453; 583-591; and in particular embodiment, between 446- 447 (SEQ ID NO: 62).
- AAV5 137; 252-262; 442-445; 574-582; and in particular embodiment, between 445- 446 (SEQ ID NO:63).
- AAV6 138; 262-272; 450-459; 585-593; and in particular embodiment, between 452-
- AAV7 138; 263-273; 451-461; 586-594; and in particular embodiment, between 453-
- AAV8 138; 263-274; 451-461; 587-595; and in particular embodiment, between 453-
- AAV9 138; 262-273; 452-461; 585-593; and in particular embodiment, between 454-
- AAV9e 138; 262-273; 452-461; 585-593; and in particular embodiment, between 454- 455 (SEQ ID NO:68).
- AAVrhlO 138; 263-274; 452-461; 587-595; and in particular embodiment, between 454-455 (SEQ ID NO:69).
- AAVrh20 138; 263-274; 452-461; 587-595; and in particular embodiment, between 454-455 (SEQ ID NO:70).
- AAVrh39 138; 263-274; 452-461; 587-595; and in particular embodiment, between 454-455 (SEQ ID NO:73).
- AAVrh74 138; 263-274; 452-461; 587-595; and in particular embodiment, between 454-455 (SEQ ID NO:72 or SEQ ID NO: 80).
- the peptide insertion occurs between amino acid residues 588-589 of the AAV9 capsid, or between corresponding residues of another AAV type capsid as determined by an amino acid sequence alignment (for example, as in FIG. 7).
- the peptide insertion occurs immediately after amino acid residue 1451 to L461, S268 and Q588 of the AAV9 capsid sequence, or immediately after corresponding residues of another AAV capsid sequence (FIG. 7).
- one or more peptide insertions can be used in a single system.
- the capsid is chosen and/or further modified to reduce recognition of the AAV particles by the subject’s immune system, such as avoiding pre-existing antibodies in the subject. In some embodiments. In some embodiments, the capsid is chosen and/or further modified to enhance desired tropism/targeting.
- AAV vectors comprising the engineered capsids.
- the AAV vectors are non-replicating and do not include the nucleotide sequences encoding the rep or cap proteins (these are supplied by the packaging cells in the manufacture of the rAAV vectors).
- AAV-based vectors comprise components from one or more serotypes of AAV.
- AAV based vectors provided herein comprise capsid components from one or more of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV.rh8, AAV.rhlO, AAV.rh20, AAV.rh39, AAV.Rh74, AAV.RHM4-1, AAV.hu37, AAV.Anc80, AAV.Anc80L65, AAV.7m8, AAV.PHP.B, AAV.PHP.eB, AAV2.5, AAV2tYF, AAV3B, AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, AAV.HSC5, AAV.HSC6, AAV.HSC7, AAV.HSC8, AAV.HSC9, AAV.HSC
- AAV based vectors provided herein comprise components from one or more of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV.rh8, AAV.rhlO, AAV.rh20, AAV.rh39, AAV.Rh74, AAV.RHM4-1, AAV.hu37, AAV.Anc80, AAV.Anc80L65, AAV.7m8, AAV.PHP.B, AAV.PHP.eB, AAV2.5, AAV2tYF, AAV3B, AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, AAV.HSC5, AAV.HSC6, AAV.HSC7, AAV.HSC8, AAV.HSC9, AAV.HSC10, AAV.HSC
- rAAV particles comprise a capsid protein at least 80% or more identical, e.g, 85%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, etc., i.e.
- AAV capsid serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV.rh8, AAV.rhlO, AAV.rh20, AAV.rh39, AAV.Rh74, AAV.RHM4-1, AAV.hu37, AAV.Anc80, rAAV.Anc80L65, AAV.7m8, AAV.PHP.B, AAV.PHP.eB, AAV2.5, AAV2tYF, AAV3B, AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, AAV.HSC5, AAV.HSC6, AAV.HSC7, AAV.HS
- the recombinant AAV for use in compositions and methods herein is Anc80 or Anc80L65 (see, e.g., Zinn etal., 2015, Cell Rep. 12(6): 1056-1068, which is incorporated by reference in its entirety).
- the recombinant AAV for use in compositions and methods herein is AAV.7m8 (including variants thereol) (see, e.g., US 9,193,956; US 9,458,517; US 9,587,282; US 2016/0376323, and WO 2018/075798, each of which is incorporated herein by reference in its entirety).
- the AAV for use in compositions and methods herein is any AAV disclosed in US 9,585,971, such as AAV-PHP.B.
- the AAV for use in compositions and methods herein is an AAV2/Rec2 or AAV2/Rec3 vector, which has hybrid capsid sequences derived from AAV8 and serotypes cy5, rh20 or rh39 (see, e.g., Issa et al., 2013, PLoS One 8(4): e60361, which is incorporated by reference herein for these vectors).
- the AAV for use in compositions and methods herein is an AAV disclosed in any of the following, each of which is incorporated herein by reference in its entirety: US 7,282,199; US 7,906,111; US 8,524,446; US 8,999,678; US 8,628,966; US 8,927,514; US 8,734,809; US9,284,357; US 9,409,953; US 9,169,299; US 9,193,956; US 9,458,517; US 9,587,282; US 2015/0374803; US 2015/0126588; US 2017/0067908; US 2013/0224836; US 2016/0215024; US 2017/0051257; PCT/US2015/034799; and PCT/EP2015/053335.
- rAAV particles have a capsid protein at least 80% or more identical, e.g, 85%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, etc., i.e. up to 100% identical, to the VP1, VP2 and/or VP3 sequence of an AAV capsid disclosed in any of the following patents and patent applications, each of which is incorporated herein by reference in its entirety: United States Patent Nos.
- rAAV particles comprise any AAV capsid disclosed in United States Patent No. 9,840,719 and WO 2015/013313, such as AAV.Rh74 and RHM4-1, each of which is incorporated herein by reference in its entirety.
- rAAV particles comprise any AAV capsid disclosed in WO 2014/172669, such as AAV rh.74, which is incorporated herein by reference in its entirety.
- rAAV particles comprise the capsid of AAV2/5, as described in Georgiadis et al., 2016, Gene Therapy 23: 857-862 and Georgiadis et al., 2018, Gene Therapy 25: 450, each of which is incorporated by reference in its entirety.
- rAAV particles comprise any AAV capsid disclosed in WO 2017/070491, such as AAV2tYF, which is incorporated herein by reference in its entirety.
- rAAV particles comprise the capsids of AAVLK03 or AAV3B, as described in Puzzo etal., 2017, Sci. Transl. Med. 29(9): 418, which is incorporated by reference in its entirety.
- rAAV particles comprise any AAV capsid disclosed in US Pat Nos.
- rAAV particles have a capsid protein disclosed in Inti. Appl. Publ. No.
- WO 2003/052051 see, e.g, SEQ ID NO: 2 of '051 publication
- WO 2005/033321 see, e.g, SEQ ID NOs: 123 and 88 of '321 publication
- WO 03/042397 see, e.g, SEQ ID NOs: 2, 81, 85, and 97 of '397 publication
- WO 2006/068888 see, e.g, SEQ ID NOs: 1 and 3-6 of '888 publication
- WO 2006/110689 see, e.g., SEQ ID NOs: 5-38 of '689 publication
- W02009/104964 see, e.g, SEQ ID NOs: 1-5, 7, 9, 20, 22, 24 and 31 of '964 publication
- WO 2010/127097 see, e.g, SEQ ID NOs: 5-38 of '097 publication
- WO 2015/191508 see, e.g, SEQ ID NOs: 80-294 of '508 publication
- rAAV particles have a capsid protein at least 80% or more identical, e.g. , 85%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, etc., i.e. up to 100% identical, to the VP1, VP2 and/or VP3 sequence of an AAV capsid disclosed in Inti. Appl. Publ. No.
- WO 2003/052051 see, e.g, SEQ ID NO: 2 of '051 publication
- WO 2005/033321 see, e.g, SEQ ID NOs: 123 and 88 of '321 publication
- WO 03/042397 see, e.g, SEQ ID NOs: 2, 81, 85, and 97 of '397 publication
- WO 2006/068888 see, e.g, SEQ ID NOs: 1 and 3-6 of '888 publication
- WO 2006/110689 see, e.g, SEQ ID NOs: 5-38 of '689 publication
- W02009/104964 see, e.g, SEQ ID NOs: 1-5, 7, 9, 20, 22, 24 and 31 of 964 publication
- W02010/127097 see, e.g, SEQ ID NOs: 5-38 of '097 publication
- WO 2015/191508 see, e.g, SEQ ID NOs: 80-294 of '508 publication
- rAAV particles comprise a pseudotyped AAV capsid.
- the pseudotyped AAV capsids are rAAV2/8 or rAAV2/9 pseudotyped AAV capsids.
- Methods for producing and using pseudotyped rAAV particles are known in the art (see, e.g., Duan etal., J. Virol., 75:7662-7671 (2001); Halbert etal., J. Virol., 74:1524-1532 (2000); Zolotukhin et al., Methods 28:158-167 (2002); and Auricchio et al., Hum. Molec. Genet. 10:3075-3081, (2001).
- a single-stranded AAV may be used.
- a self-complementary vector e.g., scAAV
- scAAV single-stranded AAV
- an rAAV particle is made by providing a nucleotide comprising the nucleic acid sequence encoding any of the capsid proteins described herein; and using a packaging cell system to prepare corresponding rAAV particles with capsid coats made up of the capsid protein.
- the nucleic acid sequence encodes a sequence having at least 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.9%, identity to the sequence of a capsid protein molecule described herein, and retains (or substantially retains) biological function of the capsid protein.
- the nucleic acid encodes a sequence having at least 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.9%, identity to the sequence of the one of the capsid proteins described herein, for example, those with sequences in Table 17 or otherwise described herein (see also FIG. 7), while retaining (or substantially retaining) biological function of the capsid protein.
- the capsid protein, coat, and rAAV particles may be produced by techniques known in the art.
- the viral genome comprises at least one inverted terminal repeat to allow packaging into a vector.
- the viral genome further comprises a cap gene and/or a rep gene for expression and splicing of the cap gene.
- the cap and rep genes are provided by a packaging cell and not present in the viral genome.
- the nucleic acid encoding the engineered capsid protein is cloned into an AAV Rep-Cap helper plasmid in place of the existing capsid gene.
- this plasmid helps package an rAAV genome into the engineered capsid protein as the capsid coat.
- Packaging cells can be any cell type possessing the genes necessary to promote AAV genome replication, capsid assembly, and packaging. Nonlimiting examples include 293 cells or derivatives thereof, HELA cells, or insect cells.
- Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection).
- Enzymatic reactions and purification techniques can be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein.
- the foregoing techniques and procedures can be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference for any purpose.
- the rAAVs provide transgene delivery vectors that can be used in therapeutic and prophylactic applications, as discussed in more detail below.
- the rAAV vector also includes regulatory control elements known to one skilled in the art to influence the expression of the RNA and/or protein products encoded by nucleic acids (transgenes) within target cells of the subject. Regulatory control elements and may be tissue-specific, that is, active (or substantially more active or significantly more active) only in the target cell/tissue.
- the AAV vector comprises a regulatory sequence, such as a promoter, operably linked to the transgene that allows for expression in target tissues.
- the promoter may be a constitutive promoter, for example, the CB7 promoter.
- Additional promoters include: cytomegalovirus (CMV) promoter, Rous sarcoma virus (RSV) promoter, MMT promoter, EF-1 alpha promoter, UB6 promoter, chicken beta-actin promoter, CAG promoter, RPE65 promoter, opsin promoter, the TBG (Thyroxine-binding Globulin) promoter, the APOA2 promoter, SERPINA1 (hAAT) promoter, or MIR122 promoter.
- CMV cytomegalovirus
- RSV Rous sarcoma virus
- MMT Rous sarcoma virus
- EF-1 alpha promoter e.g., EF-1 alpha promoter
- UB6 promoter EF-1 alpha promoter
- UB6 promoter EF-1 alpha promoter
- UB6 promoter EF-1 alpha promoter
- UB6 promoter EF-1 alpha promoter
- UB6 promoter EF-1 alpha promoter
- AAV vectors comprising a viral genome comprising an expression cassette for expression of the transgene, under the control of regulatory elements, and flanked by ITRs and an engineered viral capsid as described herein or is at least 95%, 96%, 97%, 98%, 99% or 99.9% identical to the amino acid sequence of the a capsid protein described herein (see Table 17, e.g.), while retaining the biological function of the engineered capsid.
- the encoded engineered capsid has the sequence of an AAV8.BBB.LD capsid (SEQ ID NO: 27), an AAV9.BBB.LD capsid (SEQ ID NO: 29), an AAV9.496-NNN/AAA-498 capsid (SEQ ID NO: 31), AAV9.496-NNN/AAA-498 capsid (SEQ ID NO: 32), AAV9.
- W503R capsid (SEQ ID NO: 33), AAV9.Q474A capsid (SEQ ID NO: 34), AAV9.N272A.496-NNN/AAA-498 capsid (SEQ ID NO: 91) or AAV9.N266A.496-NNN/AAA-498 capsid (SEQ ID NO: 92).
- engineered AAV vectors other than AAV9 vectors such as engineered AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV9e, AAVrhlO, AAVrh20, AAVhu.37, AAVrh39, AAVrh74, AAVrh34, AAVhu26, AAVrh31, AAVhu56, AAVhu53, AAVrh.46, AAVrh.64.Rl, AAV.rh.73 vectors, including with the amino acid substitutions and/or peptide insert as described herein and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acid substitutions relative to the wild type or unengineered sequence for that AAV type and that retains its biological function.
- the recombinant adenovirus can be a first-generation vector, with an El deletion, with or without an E3 deletion, and with the expression cassette inserted into either deleted region.
- the recombinant adenovirus can be a second-generation vector, which contains full or partial deletions of the E2 and E4 regions.
- a helper-dependent adenovirus retains only the adenovirus inverted terminal repeats and the packaging signal (phi).
- the transgene generally is inserted between the packaging signal and the 3’ITR, with or without stuffer sequences to keep the genome close to wild-type size of approximately 36 kb.
- the rAAV vector for delivering the transgene to target tissues, cells, or organs has a tropism for that particular target tissue, cell, or organ. Tissue-specific promoters may also be used.
- the construct further can include expression control elements that enhance expression of the transgene driven by the vector (e.g., introns such as the chicken [3-actin intron, minute virus of mice (MVM) intron, human factor IX intron (e.g., FIX truncated intron 1), [3-globin splice donor/immunoglobulin heavy chain spice acceptor intron, adenovirus splice donor /immunoglobulin splice acceptor intron, SV40 late splice donor /splice acceptor (19S/16S) intron, and hybrid adenovirus splice donor/IgG splice acceptor intron and polyA signals such as the rabbit [3-globin polyA signal, human growth hormone (
- nucleic acids sequences disclosed herein may be codon- optimized, for example, via any codon-optimization technique known to one of skill in the art (see, e.g., review by Quax et al., 2015, Mol Cell 59:149-161).
- the constructs described herein comprise the following components: (1) AAV2 inverted terminal repeats that flank the expression cassette; (2) control elements, which include a) a promoter and, optionally, enhancer elements to promote expression of the transgene in CNS and/or muscle cells, b) optionally an intron sequence, such as a chicken
- control elements which include a) a promoter and, optionally, enhancer elements to promote expression of the transgene in CNS and/or muscle cells, b) optionally an intron sequence, such as a chicken
- the viral vectors provided herein may be manufactured using host cells, e.g., mammalian host cells, including host cells from humans, monkeys, mice, rats, rabbits, or hamsters.
- host cells e.g., mammalian host cells, including host cells from humans, monkeys, mice, rats, rabbits, or hamsters.
- Nonlimiting examples include: A549, WEHI, 10T1/2, BHK, MDCK, COS1, COS7, BSC 1, BSC 40, BMT 10, VERO, W138, HeLa, 293, Saos, C2C12, L, HT1080, HepG2, primary fibroblast, hepatocyte, and myoblast cells.
- the host cells are stably transformed with the sequences encoding the transgene and associated elements (i. e.
- the vector genome the vector genome
- genetic components for producing viruses in the host cells such as the replication and capsid genes (e.g. , the rep and cap genes of AAV).
- the replication and capsid genes e.g. , the rep and cap genes of AAV.
- Genome copy titers of said vectors may be determined, for example, by TAQMAN® analysis.
- Virions may be recovered, for example, by CsCh sedimentation.
- baculovirus expression systems in insect cells may be used to produce AAV vectors.
- Aponte-Ubillus et al., 2018, Appl. Microbiol. Biotechnol. 102: 1045-1054 which is incorporated by reference herein in its entirety for manufacturing techniques.
- in vitro assays can be used to measure transgene expression from a vector described herein, thus indicating, e.g., potency of the vector.
- a vector described herein e.g., the PER.C6® Cell Line (Lonza), a cell line derived from human embryonic retinal cells, or retinal pigment epithelial cells, e.g., the retinal pigment epithelial cell line hTERT RPE-1 (available from ATCC®), can be used to assess transgene expression.
- cell lines derived from liver or other cell types may be used, for example, but not limited, to HuH-7, HEK293, fibrosarcoma HT-1080, HKB-11, and CAP cells.
- characteristics of the expressed product i.e., transgene product
- characteristics of the expressed product can be determined, including determination of the glycosylation and tyrosine sulfation patterns, using assays known in the art.
- Another aspect relates to therapies which involve administering a transgene via a rAAV vector according to the invention to a subject in need thereof, for delaying, preventing, treating, and/or managing a disease or disorder, and/or ameliorating one or more symptoms associated therewith.
- a subject in need thereof includes a subject suffering from the disease or disorder, or a subject pre-disposed thereto, e.g., a subject at risk of developing or having a recurrence of the disease or disorder.
- a rAAV carrying a particular transgene will find use with respect to a given disease or disorder in a subject where the subject’s native gene, corresponding to the transgene, is defective in providing the correct gene product, or correct amounts of the gene product.
- the transgene then can provide a copy of a gene that is defective in the subject.
- the transgene comprises cDNA that restores protein function to a subject having a genetic mutation(s) in the corresponding native gene.
- the cDNA comprises associated RNA for performing genomic engineering, such as genome editing via homologous recombination.
- the transgene encodes a therapeutic RNA, such as a shRNA, artificial miRNA, or element that influences splicing.
- Tables 1A-1B below provides a list of transgenes that may be used in any of the rAAV vectors described herein, in particular, in the novel insertion sites described herein, to treat or prevent the disease with which the transgene is associated, also listed in Tables 1A- 1B.
- the AAV vector may be engineered as described herein to target the appropriate tissue for delivery of the transgene to effect the therapeutic or prophylactic use.
- the appropriate AAV serotype may be chosen to engineer to optimize the tissue tropism and transduction of the vector.
- a rAAV vector comprising a transgene encoding glial derived growth factor (GDGF) finds use treating/preventing/managing Parkinson’s disease.
- the rAAV vector is administered systemically.
- the rAAV vector may be provided by intravenous, intrathecal, intra-nasal, and/or intra-peritoneal administration.
- the transgene encodes a microdystrophin (for example, as disclosed in WO WO2021/108755, W02002/029056, WO2016/115543, WO2015/197232, WO2016/177911, US7892824B2, US9624282B2, and WO2017221145, which are hereby incorporated by reference in their entirety) and is useful for treatment of dystrophinopathies, such as muscular dystrophy.
- a microdystrophin for example, as disclosed in WO WO2021/108755, W02002/029056, WO2016/115543, WO2015/197232, WO2016/177911, US7892824B2, US9624282B2, and WO2017221145, which are hereby incorporated by reference in their entirety
- Example 18 herein shows the relative abundance of capsids AAV7, AAV8, AAV9, AAVrh.10, AAVrh.46, AAVrh.64.Rl, and AAVrh.73 after intravenous administration to wild-type mice compared to mdx mice (animal model for muscular dystrophy).
- rAAV particles having these capsids, or an engineered forms thereof may be useful for delivery of transgenes encoding microdystrophins or other dystrophinopathy therapeutic proteins to muscle cells, including skeletal and/or cardiac muscle, while having reduced delivery to liver cells, for treatment of muscular dystrophies, such as, Duchenne Muscular Dystrophy.
- the rAAVs of the present invention find use in delivery to target tissues, or target cell types, including cell matrix associated with the target cell types, associated with the disorder or disease to be treated/prevented.
- a disease or disorder associated with a particular tissue or cell type is one that largely affects the particular tissue or cell type, in comparison to other tissue of cell types of the body, or one where the effects or symptoms of the disorder appear in the particular tissue or cell type.
- Methods of delivering a transgene to a target tissue of a subject in need thereof involve administering to the subject tan rAAV where the peptide insertion is a homing peptide.
- a rAAV vector comprising a peptide insertion that directs the rAAV to neural tissue can be used, in particular, where the peptide insertion facilitates the rAAV in crossing the blood brain barrier to the CNS.
- an rAAV vector can be used that comprises a peptide insertion from a neural tissue-homing domain, such as any described herein.
- Diseases/disorders associated with neural tissue include Alzheimer's disease, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis (ALS), Battens disease, Batten’s Juvenile NCL form, Canavan disease, chronic pain, Friedreich’s ataxia, glioblastoma multiforme, Huntington's disease, Late Infantile neuronal ceroid lipofuscinosis (LINCL), lysosomal storage disorders, Leber’s congenital amaurosis, multiple sclerosis, Parkinson's disease, Pompe disease, Rett syndrome, spinal cord injury, spinal muscular atrophy (SMA), stroke, and traumatic brain injury.
- the vector further can contain a transgene for therapeutic/ prophylactic benefit to a subject suffering from, or at risk of developing, the disease or disorder (see
- the rAAV vectors of the invention also can facilitate delivery, in particular, targeted delivery, of oligonucleotides, drugs, imaging agents, inorganic nanoparticles, liposomes, antibodies to target cells or tissues.
- the rAAV vectors also can facilitate delivery, in particular, targeted delivery, of non-coding DNA, RNA, or oligonucleotides to target tissues.
- the agents may be provided as pharmaceutically acceptable compositions as known in the art and/or as described herein. Also, the rAAV molecule of the invention may be administered alone or in combination with other prophylactic and/or therapeutic agents. [00162]
- the dosage amounts and frequencies of administration provided herein are encompassed by the terms therapeutically effective and prophylactically effective. The dosage and frequency will typically vary according to factors specific for each patient depending on the specific therapeutic or prophylactic agents administered, the severity and type of disease, the route of administration, as well as age, body weight, response, and the past medical history of the patient, and should be decided according to the judgment of the practitioner and each patient's circumstances.
- Suitable regimens can be selected by one skilled in the art by considering such factors and by following, for example, dosages reported in the literature and recommended in the Physician 's Desk Reference (56 th ed., 2002).
- Prophylactic and/or therapeutic agents can be administered repeatedly. Several aspects of the procedure may vary such as the temporal regimen of administering the prophylactic or therapeutic agents, and whether such agents are administered separately or as an admixture.
- the amount of an agent of the invention that will be effective can be determined by standard clinical techniques. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. For any agent used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (z.e., the concentration of the test compound that achieves a half- maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
- Prophylactic and/or therapeutic agents can be tested in suitable animal model systems prior to use in humans.
- animal model systems include, but are not limited to, rats, mice, chicken, cows, monkeys, pigs, dogs, rabbits, etc. Any animal system well-known in the art may be used. Such model systems are widely used and well known to the skilled artisan.
- animal model systems for a CNS condition are used that are based on rats, mice, or other small mammal other than a primate.
- prophylactic and/or therapeutic agents of the invention Once the prophylactic and/or therapeutic agents of the invention have been tested in an animal model, they can be tested in clinical trials to establish their efficacy. Establishing clinical trials will be done in accordance with common methodologies known to one skilled in the art, and the optimal dosages and routes of administration as well as toxicity profiles of agents of the invention can be established. For example, a clinical trial can be designed to test a rAAV molecule of the invention for efficacy and toxicity in human patients.
- Toxicity and efficacy of the prophylactic and/or therapeutic agents of the instant invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g, for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Prophylactic and/or therapeutic agents that exhibit large therapeutic indices are preferred. While prophylactic and/or therapeutic agents that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such agents to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- a rAAV molecule of the invention generally will be administered for a time and in an amount effective for obtain a desired therapeutic and/or prophylactic benefit.
- the data obtained from the cell culture assays and animal studies can be used in formulating a range and/or schedule for dosage of the prophylactic and/or therapeutic agents for use in humans.
- the dosage of such agents lies within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- a therapeutically effective dosage of an rAAV vector for patients is generally from about 0.1 ml to about 100 ml of solution containing concentrations of from about IxlO 9 to about IxlO 16 genomes rAAV vector, or about IxlO 10 to about IxlO 15 , about IxlO 12 to about IxlO 16 , or about IxlO 14 to about IxlO 16 AAV genomes.
- concentrations of from about IxlO 9 to about IxlO 16 genomes rAAV vector or about IxlO 10 to about IxlO 15 , about IxlO 12 to about IxlO 16 , or about IxlO 14 to about IxlO 16 AAV genomes.
- Levels of expression of the transgene can be monitored to determine/adjust dosage amounts, frequency, scheduling, and the like.
- Treatment of a subject with a therapeutically or prophylactically effective amount of the agents of the invention can include a single treatment or can include a series of treatments.
- pharmaceutical compositions comprising an agent of the invention may be administered once, or may be administered in a series of 2, 3 or 4 or more times, for example, weekly, monthly or every two months, 3 months, 6 months or one year until the series of doses has been administered.
- the rAAV molecules of the invention may be administered alone or in combination with other prophylactic and/or therapeutic agents.
- Each prophylactic or therapeutic agent may be administered at the same time or sequentially in any order at different points in time; however, if not administered at the same time, they should be administered sufficiently close in time so as to provide the desired therapeutic or prophylactic effect.
- Each therapeutic agent can be administered separately, in any appropriate form and by any suitable route.
- the different prophylactic and/or therapeutic agents are administered less than 1 hour apart, at about 1 hour apart, at about 1 hour to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, no more than 24 hours apart, or no more than 48 hours apart.
- two or more agents are administered within the same patient visit.
- Methods of administering agents of the invention include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous, including infusion or bolus injection), epidural, and by absorption through epithelial or mucocutaneous or mucosal linings (e.g., intranasal, oral mucosa, rectal, and intestinal mucosa, etc.).
- the vector is administered via lumbar puncture or via cistema magna.
- the agents of the invention are administered intravenously and may be administered together with other biologically active agents.
- agents of the invention may be delivered in a sustained release formulation, e.g., where the formulations provide extended release and thus extended half-life of the administered agent.
- Controlled release systems suitable for use include, without limitation, diffusion-controlled, solvent-controlled, and chemically-controlled systems.
- Diffusion controlled systems include, for example reservoir devices, in which the molecules of the invention are enclosed within a device such that release of the molecules is controlled by permeation through a diffusion barrier.
- Common reservoir devices include, for example, membranes, capsules, microcapsules, liposomes, and hollow fibers.
- Monolithic (matrix) device are a second type of diffusion controlled system, wherein the dual antigenbinding molecules are dispersed or dissolved in an rate-controlling matrix (e.g, a polymer matrix).
- an rate-controlling matrix e.g, a polymer matrix
- Agents of the invention can be homogeneously dispersed throughout a rate-controlling matrix and the rate of release is controlled by diffusion through the matrix.
- Polymers suitable for use in the monolithic matrix device include naturally occurring polymers, synthetic polymers and synthetically modified natural polymers, as well as polymer derivatives. [00175] Any technique known to one of skill in the art can be used to produce sustained release formulations comprising one or more agents described herein. See, e.g. U.S. Pat. No.
- a pump may be used in a controlled release system (see Langer, supra,- Sefton, CRC Crit. Ref. Biomed. Eng., 14:20, 1987; Buchwald et al., Surgery, 88:507, 1980; and Saudek et al., N. Engl. J. Med., 321:574, 1989).
- polymeric materials can be used to achieve controlled release of agents comprising dual antigen-binding molecule, or antigen-binding fragments thereof (see e.g., Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, N.Y. (1984); Ranger and Peppas, J., Macromol. Sci. Rev. Macromol. Chem., 23:61, 1983; see also Levy et al., Science, 228:190, 1985; During et al., Ann.
- a controlled release system can be placed in proximity of the therapeutic target (e.g, an affected joint), thus requiring only a fraction of the systemic dose (see, e.g, Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115 138 (1984)). Other controlled release systems are discussed in the review by Langer, Science, 249:1527 1533, 1990.
- rAAVs can be used for in vivo delivery of transgenes for scientific studies such as optogenetics, gene knock-down with miRNAs, recombinase delivery for conditional gene deletion, gene editing with CRISPRs, and the like. 5.5. Pharmaceutical Compositions and Kits
- the invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an agent of the invention, said agent comprising a rAAV molecule of the invention.
- the pharmaceutical composition comprises rAAV combined with a pharmaceutically acceptable carrier for administration to a subject.
- pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- carrier refers to a diluent, adjuvant (e.g., Freund's complete and incomplete adjuvant), excipient, or vehicle with which the agent is administered.
- Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, including, e.g., peanut oil, soybean oil, mineral oil, sesame oil and the like.
- Water is a common carrier when the pharmaceutical composition is administered intravenously.
- Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- compositions include, but are not limited to, buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin and gelatin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; saltforming counterions such as sodium; and/or nonionic surfactants such as TWEENTM, polyethylene glycol (PEG), and PLURONICSTM as known in the art.
- buffers such as phosphate, citrate, and other organic acids
- antioxidants including ascorbic acid
- low molecular weight polypeptides proteins, such as serum albumin and gelatin
- hydrophilic polymers such as poly
- the pharmaceutical composition of the present invention can also include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, and a preservative, in addition to the above ingredients.
- a lubricant e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol
- compositions are provided for use in accordance with the methods of the invention, said pharmaceutical compositions comprising a therapeutically and/or prophylactically effective amount of an agent of the invention along with a pharmaceutically acceptable carrier.
- the agent of the invention is substantially purified (i.e., substantially free from substances that limit its effect or produce undesired side-effects).
- the host or subject is an animal, e.g, a mammal such as non-primate (e.g, cows, pigs, horses, cats, dogs, rats etc.) and a primate (e.g, monkey such as, a cynomolgus monkey and a human).
- the host is a human.
- kits that can be used in the above methods.
- a kit comprises one or more agents of the invention, e.g., in one or more containers.
- a kit further comprises one or more other prophylactic or therapeutic agents useful for the treatment of a condition, in one or more containers.
- the invention also provides agents of the invention packaged in a hermetically sealed container such as an ampoule or sachette indicating the quantity of the agent or active agent.
- the agent is supplied as a dry sterilized lyophilized powder or water free concentrate in a hermetically sealed container and can be reconstituted, e.g , with water or saline, to the appropriate concentration for administration to a subject.
- the agent is supplied as a dry sterile lyophilized powder in a hermetically sealed container at a unit dosage of at least 5 mg, more often at least 10 mg, at least 15 mg, at least 25 mg, at least 35 mg, at least 45 mg, at least 50 mg, or at least 75 mg.
- an agent of the invention is supplied in liquid form in a hermetically sealed container indicating the quantity and concentration of agent or active agent.
- the liquid form of the agent is supplied in a hermetically sealed container at least 1 mg/ml, at least 2.5 mg/ml, at least 5 mg/ml, at least 8 mg/ml, at least 10 mg/ml, at least 15 mg/kg, or at least 25 mg/ml.
- compositions of the invention include bulk drug compositions useful in the manufacture of pharmaceutical compositions (e.g, impure or non-sterile compositions) as well as pharmaceutical compositions (i.e., compositions that are suitable for administration to a subj ect or patient).
- Bulk drug compositions can be used in the preparation of unit dosage forms, e.g., comprising a prophylactically or therapeutically effective amount of an agent disclosed herein or a combination of those agents and a pharmaceutically acceptable carrier.
- the invention further provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the agents of the invention. Additionally, one or more other prophylactic or therapeutic agents useful for the treatment of the target disease or disorder can also be included in the pharmaceutical pack or kit.
- the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use, or sale for human administration.
- compositions of the invention are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of agent or active agent.
- a hermetically sealed container such as an ampoule or sachette indicating the quantity of agent or active agent.
- the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
- an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
- the following examples report an analysis of surface-exposed loops on the AAV9 capsid to identify candidates for capsid engineering via insertional mutagenesis.
- the invention is illustrated by way of examples, describing the construction of rAAV9 capsids engineered to contain 7-mer peptides designed on the basis of the human axonemal dynein heavy chain tail. Briefly, three criteria were used for selecting surface loops that might be amenable to short peptide insertions: 1) minimal side chain interactions with adjacent loops; 2) variable sequence and structure between serotypes (lack of conserved sequences); and 3) the potential for interrupting commonly targeted neutralizing antibody epitopes.
- a panel of peptide insertion mutants was constructed and the individual mutants were screened for viable capsid assembly, peptide surface exposure, and potency. The top candidates were then used as templates for insertion of homing peptides to test if these peptide insertion points could be used to re-target rAAV vectors to tissues of interest. Further examples, demonstrate the increased transduction and tissue tropism for certain of the modified AAV capsids described herein.
- FIGs. 1 and 2 depict analysis of variable region four of the adeno-associated virus type 9 (AAV9 VR-IV) by amino acid sequence comparison to other AAVs VR-IV (FIG. 1) and protein model (FIG. 2). As seen, AAV9 VR-IV is exposed on the surface at the tip or outer surface of the 3-fold spike. Further analysis indicated that there are few side chain interactions between VR-IV and VR-V and that the sequence and structure of VR-IV is variable amongst AAV serotypes, and further that there is potential for interrupting a commonly-targeted neutralizing antibody epitope and thus, reducing immunogenicity of the modified capsid.
- AAV9 VR-IV adeno-associated virus type 9
- AAV9 mutants were constructed, to each include a heterologous peptide but at different insertion points in the VR-IV loop.
- the heterologous peptide was a FLAG tag that was inserted immediately following the following residues in vectors identified as pRGNXl 090- 1097, as shown in Table 2.
- FIG. 3 depicts high packaging efficiency in terms of genome copies per mL (GC/mL) of wild type AAV9 and eight (8) candidate rAAV9 vectors (1090, 1091, 1092, 1093, 1094, 1095, 1096, and 1097), where the candidate vectors each contain a FLAG insert at different sites within AAV9’s VR-IV. All vectors were packaged with luciferase transgene in 10 mL culture to facilitate determining which insertion points did not interrupt capsid packaging; error bars represent standard error of the mean.
- FIG. 4 depicts surface exposure of FLAG inserts in each of eight (8) candidate rAAV9 vectors (1090, 1091, 1092, 1093, 1094, 1095, 1096, and 1097), confirmed by immunoprecipitation of transduced vectors by binding to anti-FLAG resin. Binding to anti- FLAG indicates insertion points that allow formation of capsids that display the peptide insertion on the surface.
- 1090 had the lowest titer of the candidate vectors, indicating the least protein pulled down. Very low titers also were seen with the positive control. It is likely that not a sufficient amount of positive control had been loaded for visualization on SDS-PAGE.
- FIGs. 5A-5B depict transduction efficiency in Lec2 cells, transduced with capsid vectors carrying the luciferase gene as a transgene, that was packaged into either wild type AAV9 (9-luc), or into each of eight (8) candidate rAAV9 vectors (1090, 1091, 1092, 1093, 1094, 1095, 1096, and 1097); activity is expressed as percent luciferase activity, taking the activity of 9-luc as 100% (FIG. 5A), or as Relative Light Units (RLU) per microgram of protein (FIG. 5B)
- CHO-derived Lec2 cells were grown in aMEM and 10% FBS.
- the Lec2 cells were transduced at a MOI of about 2x10 8 GC vector (a MOI of about 10,000) and were treated with ViraDuctin reagent (similar results were observed on transducing Lec2 cells at a MOI of about 10,000 GC/cell but treated with 40 pg/mL zinc chloride (ZnCh); results not shown).
- Lec2 cells are proline auxotrophs from CHO.
- transduction efficiency in vitro is lower than that obtained using wild type AAV9 (9-luc). Nonetheless, previous studies have shown that introduction of a homing peptide can decrease in vitro gene transfer in non-target cells (such as 293, Lec2, or HeLa), while significantly increasing in vitro gene transfer in target cells (see, e.g., Nicklin et al. 2001; and Grifman et al. 2001).
- non-target cells such as 293, Lec2, or HeLa
- FIG. 6A depicts a bar graph illustrating that insertions immediately after S454 of AAV9 capsid (SEQ ID NO:67) of varying peptide length and composition may affect production efficiencies of AAV particles in a packaging cell line.
- Ten peptides of varying composition and length were inserted after S454 (between residues 454 and 455) within AAV9 VR-IV.
- qPCR was performed on harvested supernatant of transfected suspension HEK293 cells five days post-transfection.
- the results depicted in the bar graph demonstrate that the nature and length of the insertions may affect the ability of AAV particles to be produced at high titer and packaged in 293 cells. (Error bars represent standard error of the mean length of peptide, which is noted on the Y-axis in parenthesis.)
- AAV9 vectors having a capsid protein containing a homing peptide of the following peptide sequences (Table 3) at the S454 insertion site were studied.
- Suspension-adapted HEK293 cells were seeded at IxlO 6 cells/mL one day before transduction in lOmL of media.
- Triple plasmid DNA transfections were done with PEIpro® (Polypus transfection) at a DNA:PEI ratio of 1:1.75. Cells were spun down and supernatant harvested five days posttransfection and stored at -80°C.
- qPCR was performed on harvested supernatant of transfected suspension HEK293 cells five days post-transfection. Samples were subjected to DNase I treatment to remove residual plasmid or cellular DNA and then heat treated to inactivate DNase I and denature capsids. Samples were titered via qPCR using TaqMan Universal PCR Master Mix, No AmpEraseUNG (ThermoFisherScientific) and primer/probe against the polyA sequence packaged in the transgene construct. Standard curves were established using RGX-501 vector BDS.
- Example 7 Homing peptides alter the transduction properties of AAV9 in vitro when inserted after S454.
- FIGs. 6B-E depict fluorescence images of cell cultures of (FIG. 6B) Lec2 cell line (sialic acid-deficient epithelial cell line) (FIG. 6C) HT-22 cell line (neuronal cell line), (FIG. 6D) hCMEC/D3 cell line (brain endothelial cell line), and (FIG. 6E) C2C12 cell line (muscle cell line).
- Lec2 cell line sialic acid-deficient epithelial cell line
- FIG. 6C HT-22 cell line
- FIG. 6D hCMEC/D3 cell line
- brain endothelial cell line hCMEC/D3 cell line
- C2C12 cell line muscle cell line.
- AAV9 wild type and S454 insertion homing peptide capsids of Table 3 containing GFP transgene were used to transduce the noted cell lines.
- Cell lines were plated at 5-20xl0 3 cells/well (depending on the cell line) in 96-well 24 hours before transduction. Cells were transduced with AAV9-GFP vectors (with or without insertions) at 1x10 10 particles/well and analyzed via Cytation5 (BioTek) 48-96 hours after transduction, depending on the difference in expression rate in each cell line.
- Lec2 cells were cultured as in Example 5, blood-brain barrier hCMEC/D3 (EMD Millipore) cells were cultured according to manufacturer’s protocol, HT-22 and HUH7 cells were cultured in DMEM and 10% FBS, and C2C12 myoblasts were plated in DMEM and 10% FBS and differentiated for three days pre-transfection in DMEM supplemented with 2% horse serum and 0.1% insulin.
- AAV9.S454.FLAG showed low transduction levels in every cell type tested.
- FIG. 7 depicts alignment of AAVs l-9e, rhlO, rh20, rh39, rh74, hu!2, hu21, hu26, hu37, hu51 and hu53 capsid sequences within insertion sites for capsid sequences within insertion sites for human peptides within or near the initiation codon of VP2, variable region 1 (VR-I), variable region 4 (VR-IV), and variable region 8 (VR-VIII) highlighted in grey; a particular insertion site within variable region eight (VR-VIII) of each capsid protein is shown by the symbol (after amino acid residue 588 according to the amino acid numbering of AAV9).
- FIG. 8 depicts copies of GFP (green fluorescent protein) transgene expressed in mouse brain cells, following administration of the AAV vectors: AAV9; AAV.PHP.eB; AAV.hDyn (AAV9 with TLAAPFK (SEQ ID NO:1) between 588-589 with no other amino acid modifications to the capsid sequence); AAV. PHP. S; and AAV. PHP. SH (see Table 17).
- AAV. PHP. B is a capsid having a TLAVPFK (SEQ ID NO:20) insertion in AAV9 capsid, with no other amino acid modifications to the capsid sequence.
- AAV.PHP.eB is a capsid having a TLAVPFK (SEQ ID NO:20) insertion in AAV9 capsid, with two amino acid modifications of the capsid sequence upstream of the PHP.B insertion (see also Table 17).
- Table 4A summarizes the capsids utilized in the study. Table. 4A
- mice were 8-12 weeks of age at the start date. At day 15 post administration, the animals were euthanized, and peripheral tissues were collected, including brain tissue, liver, forelimb biceps, heart, kidney, lung, ovaries, and the sciatic nerve.
- Quantitative PCR was used to determine the number of vector genomes per pg of brain genomic DNA. Brain samples from injected mice were processed and genomic DNA was isolated using Blood and Tissue Genomic DNA kit from Qiagen. The qPCR assay was run on a QuantStudio 5 instrument (Life Technologies Inc) using primer-probe combination specific for eGFP following a standard curve method.
- AAV vector genome copies per pg of brain genomic DNA was at least a log higher in mice that were administered AAV.hDyn compared to all other AAV serotypes: AAV9, AAV.PHPeB, PHP.S, and PHP.SH (see FIG. 8).
- AAV.hDyn which is AAV9 capsid containing the “TLAAPFK” (SEQ ID NO:1) peptide insert (a peptide from human axonemal dynein) between residues 588-589 of the AAV9 capsid.
- Other modified AAV9 capsids, however, including the vector AAV.PHPeB, which contains the “TLAVPFK” (SEQ ID NO:20) sequence demonstrated transduction in mouse brain at less than 1E03 GC/pg transgene upon systemic treatment.
- FIG. 9A depicts the amino acid sequence for a recombinant AAV9 vector capsid including a peptide insertion of amino acid sequence TLAAPFK (SEQ ID NO: 1) between Q588 and A589 of VR-IIIV . Inserted peptide in bold.
- FIG. 9B depicts the amino acid sequence for a recombinant AAV9 vector capsid including a peptide insertion of amino acid sequence TLAAPFK (SEQ ID NO: 1) between S268 and S269 of VR-III. Inserted peptide in bold.
- FIG. 9C depicts the amino acid sequence for a recombinant AAV9 vector capsid including a peptide insertion of amino acid sequence TLAAPFK (SEQ ID NO: 1) between S454 and G455 of VR-IV. Inserted peptide in bold.
- AAV capsid sequences were modified either by peptide insertions or guided mutagenesis and pooled to give a bar-coded library packaged with a GFP expression cassette.
- the modified vectors were then evaluated in an in vitro assay, as well as for in vivo biodistribution in mice using next generation sequencing (NGS) and quantitative PCR.
- NGS next generation sequencing
- AAV.hDyn was identified as a high brain transduction vector from this pool and was further evaluated in individual delivery studies in mice to characterize its transduction profile. Additionally, immunohistochemistry analysis of brain sections was performed to understand the cellular tropism of this vector. 6.11.1
- FIGS. 10A-10B depict an in vitro transwell assay for AAV.hDyn (AAV9 with TLAAPFK (SEQ ID NO:1) between amino acid residues 588-589) crossing a blood brain barrier (BBB) cell layer (FIG. 10A), and results showing that AAV.hDyn (indicated by inverted triangles in the figure) crosses the BBB cell layer of the assay faster than AAV9 (squares), as well as faster and to a greater extent than AAV2 (circles) (FIG. 10B).
- the developed in vitro assay predicted enhanced BBB cross-trafficking and similar assays can be used to predict targeting to other organs as well.
- Capsid modifications were performed on widely used AAV capsids including AAV 8, AAV9, and AAVrh.10 by inserting various peptide sequences after the position S454 of the VR-IV (Tables 5a-5c) or after position Q588 of the VR-VIII surface exposed loop of the AAV capsid, as well as insertions after the initiation codon of VP2, which begins at amino acid 137 (AAV4, AAV4-4, and AAV5) or at amino acid 138 (AAV1, AAV2, AAV3, AAV3-3, AAV6, AAV7, AAV8, AAV9, AAV9e, rh.10, rh.20, rh.39, rh.74, and hu.37) (FIG.
- rAAVs with certain modified capsids were tested for transduction in vitro in Lec2 cells as described above in Example 5.
- Modified AAVs tested for transduction in Lec2 cells as follows: eB 588 Ad, eB 588 Hep, eB 588 p79, eB 588 Rab, AAV9588 Ad, AAV9588 Hep, AAV9 588 p79, AAV9 588 Rab, eB VP2 Ad, eB VP2 Hep, eB VP2 p79, eB VP2 Rab, AAV9 VP2 Ad, AAV9 VP2 Hep, AAV9 VP2 p79, AAV9 VP2 Rab as compared to AAV9. See Table 5B below for identity of AAV capsids.
- modified AAVs were packaged with an eGFP transgene cassette containing specific barcodes corresponding to each individual capsid. Novel barcoded vectors were pooled and injected into mice in order to increase the efficiency of screening.
- mice were randomized into treatment groups based on Day 1 body weight and their age at start date was 8-12 weeks. At day 15 post administration, the animals were euthanized and peripheral tissues were collected, including brain, kidney, liver, sciatic nerve, lung, heart, and muscle tissue. In the studies where selected capsids from the pool were injected individually, the same protocol was followed.
- Genomic DNA was isolated from tissue samples using DNeasy Blood and Tissue kit (69506) from Qiagen. Each vector’s barcode region was amplified with primers containing overlaps for NGS and unique dual indexing (UDI) and multiplex sequencing strategies, as recommended by the manufacturer (Illumina). Illumina MiSeq using reagent nano and micro kits v2 (MS-103-1001/1002) were used to determine the relative abundance of each barcoded AAV vector per sample collected from the mice. Accordingly, each vector sample in Tables 5A-C below was barcoded as noted above to allow for each read to be identified and sorted before the final data analysis. The data was normalized based on the composition of AAVs in the originally injected pool and quantified using the total genome copy number obtained from qPCR analysis with a primer-probe combination specific to the barcoded sample.
- mice injected with AAV.hDyn were sectioned using a Vibratome (Leica, VT-1000) and the GFP expression was evaluated using an anti-GFP antibody (AB3080, Millipore Sigma), Vectastain ABC kit (PK-6100, Vector Labs) and DAB Peroxidase kit (SK-4100, Vector Labs).
- GFP expressing cells were present throughout the brain in mice injected with AAV.hDyn, including distribution in the cortex, striatum, and hippocampus of the brain.
- FIGS. 13A-13C show the images from these regions and the scale bar is 400um (discussed below).
- Results are shown in FIG. 11, FIGs. 12A-12H, and FIGs. 13A-13C.
- AAV9 588 Hep AAV9 with the peptide TILSRSTQTG (SEQ ID NO: 15) 5 inserted after position 588) exhibited significantly greater transduction (4-fold) than wild type AAV9
- AAV9 VP2 Ad AAV9 with the peptide SITLVKSTQTV (SEQ ID NO: 14) inserted after position 138
- AAV9 VP2 Hep AAV9 with the peptide TILSRSTQTG (SEQ ID NO: 15) inserted after position 138
- AAV9 VP2 Rab AAV9 with the peptide RSSEEDKSTQTT (SEQ ID NO: 19) inserted after position 138
- the other AAVs assayed exhibited lower levels of transduction than AAV9.
- FIG. 11 depicts results of Next Generation Sequencing (NGS) analysis of brain gDNA, revealing relative abundances (percent composition) of the capsid pool delivered to mouse brains following intravenous injection.
- NGS Next Generation Sequencing
- the data was normalized based on the composition of AAVs in the originally injected pool and quantified using the total genome copy number obtained from qPCR analysis with a primer-probe combination specific to the eGFP sequence. Data shown are from three different experiments. Dotted lines indicate which vectors were pooled together. Parental AAV9 was used as standard and included in each pool.
- the “BC” identifiers are as indicated in Tables 5A, 5B and 5C above.
- FIG. 12A-12H depict an in vivo transduction profile of AAV.hDyn in female C57B1/6 mice, showing copy number/microgram gDNA in naive mice, or mice injected with either AAV9 or AAV.hDyn in brain (FIG. 12A), liver (FIG. 12B), heart (FIG. 12C), lung (FIG. 12D), kidney (FIG. 12E), skeletal muscle (FIG. 12F), sciatic nerve (FIG. 12G), and ovary (FIG. 12H), where AAV.hDyn shows increased brain bio-distribution compared to AAV9.
- the AAV vector genome copies per pg of brain genomic DNA was at least a log higher in mice that were administered AAV.hDyn compared to the parental AAV9 vector.
- FIGs. 13A-13C show images from the regions analysed in the Immunohistochemical Analysis described above; scale bar is 400 pm.
- AAV capsid modifications performed either by insertions in surface exposed loops of VR-IV and VR-VIII or by specific amino acid mutations did not affect their packaging efficiency and were able to produce similar titers in the production system described herein.
- Intravenous administration of AAV9 S454 Kidneyl and AAV9 S454 KidneylC to mice resulted in higher relative abundance of the viral genome and greater kidney cell transduction than other modified AAV9 vectors and the parental AAV9 vector tested.
- Intravenous administration of the AAV9 S454 Kidneyl or AAV9 S454 Musclel vector to mice resulted also in lower liver cell transduction.
- FIG. 25 depicts the amino acid sequence for a recombinant AAV9 vector capsid including a peptide insertion of amino acid sequence TLAVPFK (SEQ ID NO:20) between S454 and G455 of VR-IV.
- the administration, in vivo and post-mortem observations, and biodistribution of a pool of recombinant AAVs having engineered capsids and a GFP trans gene will be evaluated following a single intravenous, intracerebroventricular or intravitreal injection in cynomolgus monkeys (Table 7).
- the pool contains multiple capsids each of which contains a unique barcode identification allowing identification using next generation sequencing (NGS) analysis following administration to cynomolgus monkeys.
- NGS next generation sequencing
- the cynomolgus monkey is chosen as the test system because of its established usefulness and acceptance as a model for AAV biodistribution studies in a large animal species and for further translation to human. All animals on this study are naive with respect to prior treatment.
- the pool may comprise at least the following recombinant AAVs having the engineered capsids listed in Table 7. Table 7. Recombinant AAVs for Cynomolgus monkey study
- the IV infusion will be administered at a rate of 3 mL/min followed by 0.2 mL of vehicle to flush the dose from the IV catheter.
- the three intravenous animals will receive a single dose of the pooled recombinant AAVs at a volume of 4 mL/kg.
- the total dose (vg) and dose volume (mL/kg) will be recorded in the raw data.
- the IV dose of IxlO 13 GC/kg body weight was determined to be required to have the desired distribution in the CNS from a systemic delivery as well as the peripheral tissues including skeletal muscle.
- the ICV implanted animals will receive a single bolus dose at a volume of 1 mL of AAV-NAV-GFPbc (by slow infusion, approximately 0.1 mL/min) followed by 0.1 mL of vehicle to flush the dose from the catheter system.
- the ICV dose is based on distribution data from a previous non-human primate study to support current clinical programs.
- IVT intravitreal
- Clinical signs will be recorded at least once daily beginning approximately two weeks prior to initiation of dosing and continuing throughout the study period. The animals will be observed for signs of clinical effects, illness, and/or death. Additional observations may be recorded based upon the condition of the animal at the discretion of the Study Director and/or technicians.
- Ophthalmological examinations will be performed on Group 3 animals prior to dose administration, and on Days 2, 8, 15 and 22. All animals will be sedated with ketamine hydrochloride IM for the ophthalmologic examinations performed following Day 1.
- the animals will be sedated with injectable anesthesia (refer to Section 15.3.3).
- the eyes will be dilated with 1% tropicamide prior to the examination.
- the examination will include slit-lamp biomicroscopy and indirect ophthalmoscopy. Additionally, applanation tonometry will be performed on Group 3 animals prior to dosing, immediately following dose administration ( ⁇ 10 to 15 minutes) and on Days 2 and 22.
- Blood samples (-3 mL) will be collected from a peripheral vein for neutralizing antibodies analysis approximately 2 to 3 weeks prior to dose administration.
- Blood samples (-5 mL) will be collected from fasted animals from a peripheral vein for PBMC analysis prior to dose administration (Day 1), on Days 8 and 15 and prior to necropsy (Day 22). The samples will be obtained using lithium heparin tubes and the times recorded.
- Blood samples will be collected from a peripheral vein for bioanalytical analysis prior to dose administration (Day 1, 2 mL) and necropsy (Day 22, 5 mL). The samples will be collected in clot tubes and the times recorded. The tubes will be maintained at room temperature until fully clotted, then centrifuged at approximately 2400 rpm at room temperature for 15 minutes. The serum will be harvested, placed in labeled vials (necropsy sample split into 1 mL aliquots), frozen in liquid nitrogen, and stored at -60°C or below.
- CSF ( ⁇ 1.5 mL) will be collected prior to dose administration from a cistema magna spinal tap from animals in Group 1 only.
- CSF (-2 mL) will be collected immediately prior to necropsy from a cistema magna spinal tap from all animals (Groups 1 to 3).
- An attempt to collect CSF will be made but due to unsuccessful spinal taps, samples may not be collected at all intervals from an animal(s). Upon collection, the samples will be stored on ice until processing.
- a gross necropsy will be performed on any animal found dead or sacrificed moribund, and at the scheduled necropsy, following at least 21 days of treatment (Day 22). All animals, except those found dead, will be sedated with 8 mg/kg of ketamine HC1 IM, maintained on an isoflurane/oxygen mixture and provided with an intravenous bolus of heparin sodium, 200 lU/kg. The animals will be perfused via the left cardiac ventricle with 0.001% sodium nitrite in saline. Animals found dead will be necropsied but will not be perfused.
- PBMC samples collected from all animals will be evaluated by flow cytometry and enzyme-linked immune absorbent spot (ELISpot), if required.
- ELISpot enzyme-linked immune absorbent spot
- Example 13 A procedure like that described in Example 13 was used to study the biodistribution of a pool of rAAV capsids administered intravenously to cynomolgus monkey model.
- Several capsids exhibited good spread in CNS with high relative abundance (RA, compared to AAV9 reference capsid) in most brain regions, notably AAV4, AAV5, rh 34, hu 26, rh31, and hul3.
- Favorable capsids exhibiting CNS-tropism have DNA RA values resulting in greater than 1.1- fold increase in DNA values in at least one CNS region, except dorsal root ganglion (DRG).
- DRG dorsal root ganglion
- FIG. 15 depicts the relative abundance (RA) of the viral genomes (normalized to input) in the frontal cortex of the cynomolgus monkey model, and Table 8 lists the RA values for those capsids with the highest RA shown in FIG. 15.
- FIGS. 16 and 17 depict the RA of the viral genomes (normalized to input) in the hippocampus and the cerebellum of the cynomolgus monkey model, respectively.
- the RA of AAV.rh34 is shown by the shaded column on the left side of the graphs and the RA of AAV9 reference is showed by the shaded column in the middle or the graphs.
- FIGS. 16 and 17 show that AAV.rh34 is a top performing capsid in the intravenous administration pool
- AAV.rh34 displayed a favorable profile with respect to CNS toxicity as well.
- the rh34 capsid displayed decreased transduction in dorsal root ganglion (DRG) while exhibiting a high frontal cortex tropism (transduction efficiency).
- AAVrh34 exhibits an increased RA to AAV9 in CNS regions as follows: 1.8-fold in Hippocampus, 7.4-fold in frontal cortex, 1.9-fold in amygdala, 6.0-fold in medulla, 3.1-fold in midbrain, 1.2-fold in hypothalamus, 8.8-fold in thalamus, 13-fold in globus pallidus, 5.7-fold in SNc, 3.5-fold in dorsal raphe, 2.0-fold in claustrum, 13 -fold in putamen, 9-fold in occipital cortex, and 9.6-fold in cerebellum. Additionally, AAVrh34 exhibits a decreased RA in: DRGs: 90-99.5% , Liver: -99%, Biceps: -30%, Sciatic nerve: 83%, and Optic nerve: 17%.
- FIG. 18 depicts a Venn diagram of the: top 45 performers in FC (highest RA to AAV9), and bottom 45 performers in the cervical, thoracic, and lumbar DRGs (lowest RA to AAV9) and the AAVrh34 capsid is shown as the only capsid that was present in each group of 45 amongst the pool of capsids.
- AAV capsids with a combination of these recited characteristics are considered “DRG-friendly” capsids, such that their low rate of transduction in DRG should have minimal neurotoxicity and/or reduced or negligible axonopathy symptoms in a subject administered the AAV capsid.
- FIG. 19 depicts the RA of the viral genomes (normalized to input) in the frontal cortex of the cynomolgus monkey model, and Table 9 lists the RA values for those capsids with the highest RA shown in FIG. 19.
- FIG. 20 depicts the relative abundance of the viral genomes (normalized to input) in the hippocampus of the cynomolgus monkey model, and Table 10 lists the RA values for those capsids with the highest RA shown in FIG. 20.
- FIG. 21 depicts the relative abundance (RA) of the viral genomes (normalized to input) in the midbrain of the cynomolgus monkey model, and Table 11 lists the RA values for those capsids with the highest RA shown in FIG. 21.
- FIG. 22 depicts the RA of the viral genomes (normalized to input) in the cerebellum of the cynomolgus monkey model, and Table 12 lists the RA values for those capsids with the highest RA shown in FIG. 22. [00264] Table 12.
- FIG. 23 depicts the RA of the viral genomes (normalized to input) in the cervical DRGs of the cynomolgus monkey model, and Table 13 lists the RA values for those capsids with the highest RA shown in FIG. 23.
- FIG. 24 depicts the RA of the viral genomes (normalized to input) in the lumbar DRGs of the cynomolgus monkey model, and Table 14 lists the RA values for those capsids with the highest RA shown in FIG. 24.
- FIG. 25 depicts a Venn diagram of the top performing 15 capsids transducing the frontal cortex, hippocampus, midbrain and cerebellum following ICV administration. As indicated in the diagram, AAV6, AAV8.BBB, AAV.rh.46, and AAV1 were the only AAVs represented in each of the top performing groups.
- FIG. 26 depicts a Venn diagram of the top performing 45 capsids transducing the hippocampus and the 45 capsids with the lowest transduction values for DRG, to identify hippocampus-targeting DRG friendly capsids.
- AAV.hu.60, AAV.rh.21, AAV.PHP.hB, AAV.rh.15, AAV.rh.24, AAV9.W503R, hu.5, AAV9.Q474A, and AAV.hu.10 were the only AAVs represented in each of the groups.
- FIG. 27 depicts a Venn diagram of the top performing 40 capsids transducing the heart, biceps, and gastrocnemius and the 40 capsids with the lowest transduction values for the liver, to identify muscle-targeting liver-friendly capsids.
- AAV.PHPeB.VP2Herp was the only AAVs represented in each of the groups.
- FIG. 28 depicts a Venn diagram of the top performing 15 capsids transducing the heart, biceps, and gastrocnemius and Table 15 provides a list of the top performing capsids in three different cells of the diagram. Table 15.
- FIGS. 29A and B depict the RA of the viral genomes (normalized to input) in the gastrocnemius and the liver of the cynomolgus monkey model, respectively.
- Table 16 provides the rank of each capsid by RA values for the cynomolgus monkey model and the MDX mouse model. Capsids were ranked relative to one another in each animal to decrease variability across animals. Gastrocnemius, TA, heart, bicep, and triceps contributed 70% to the ranking for the MDX Mouse Model and the gastrocnemius, heart, and biceps contributed 70% to the ranking for the cynomolgus monkey model. Liver RA contributed 30% to rankings for each animal. The overall ranking was determined by weighting the ranking for each animal 50%.
- pooled barcoded vectors were administered to NHPs by IV injection.
- the pooled mixture consists of 118 different AAV capsids, including natural isolates and engineered AAVs, as described herein, expressing the GFP reporter gene from the universal CAG promoter.
- the intravenous study followed the protocol described in Examples 13 and 14, infra.
- Several capsids exhibited tropism that “detargeted” the liver, as such, mutated capsids exhibited lower abundance in liver tissue than the parental capsid (AAV9), e.g.
- AAV8.BBB.LD (A269S, 498-NNN/AAA-500), AAV9.BBB.LD (S263G/S269T/A273T, 496- NNN/AAA-498), AAV9.496-NNN-498, AAV9.496-NNN-498.W503R, AAV9.W503R, and AAV9.Q474A.
- AAV8 capsids having the NNN/AAA mutation exhibit overall approximately an 11 -fold reduction in transduction in liver, and 42 -fold reduction in expression of transcript in liver.
- AAV9 capsids having the NNN/AAA and W503R mutation exhibits approximately a 400-fold reduction in transduction in liver, and results in zero expression of transcript in liver. In some instances, brain distribution of these modified vectors was also diminished.
- AAV8.BBB.LD additionally exhibits a high level of transduction in gastrocnemius muscle.
- FIG. 31 depicts the biodistribution of select “liver-detargeting” (LD) vectors compared to their parental AAV9 capsid in various tissues, in NHPs following IV administration of the capsid library.
- FIG. 32 depicts the biodistribution of select LD vectors compared to their parental AAV8 capsid in various tissues, in NHPs following IV administration of the capsid library.
- LD liver-detargeting
- a fold change >1 indicates that the capsid makes up a lower percentage of the total capsid “pool” present in the blood at 24hr compared to 3hr after dosing (i.e. faster blood clearance).
- a fold change ⁇ 1 indicates that the capsid makes up a greater percentage of the total capsid “pool” present in the blood at 24hr compared to 3hr after dosing (i.e. slower clearance).
- slower clearance correlates with lower liver transduction/liver detargeting.
- FIG. 34A As represented by increase in blood retention, a depiction of the change in abundance for a given capsid in a given animal was plotted. Allowing for the calculation of the fold increase in blood retention over the baseline retention of AAV9, for example, the representations (FIGs 34A and 34B) compare that change in abundance value of the select capsid to the change in abundance of the parental capsid (setting the parental capsid to 1). Thus, various mutations to the AAV9 capsid increase retention in the circulation by 3 to 5 fold (see. e g. FIG. 34A).
- pooled barcoded vectors were administered to mdx mice by IV (tail vein) injection.
- the pooled mixture consists of 118 different AAV capsids, including natural isolates and engineered AAVs, as described herein, expressing the GFP reporter gene from the universal CAG promoter.
- the IV study followed a protocol analogous to that described in Examples 12 and 16, infra.
- RNAlater per manufacturer’s instructions
- flash frozen at -80°C until DNA and RNA analysis (biodistribution of each vector in the pool) were performed by NGS (see FIGs. 36A- 36H)
- Table 17 provides the amino acid sequences of certain engineered capsid proteins described and/or used in studies described herein. Heterologous peptides and amino acid substitutions are indicated in gray shading.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180066787.XA CN116783209A (en) | 2020-10-07 | 2021-10-07 | Recombinant adeno-associated viruses for CNS or muscle delivery |
MX2023003807A MX2023003807A (en) | 2020-10-07 | 2021-10-07 | Recombinant adeno-associated viruses for cns or muscle delivery. |
CA3193685A CA3193685A1 (en) | 2020-10-07 | 2021-10-07 | Recombinant adeno-associated viruses for cns or muscle delivery |
EP21802102.0A EP4225778A2 (en) | 2020-10-07 | 2021-10-07 | Recombinant adeno-associated viruses for cns or muscle delivery |
JP2023519433A JP2023545384A (en) | 2020-10-07 | 2021-10-07 | Recombinant adeno-associated virus for central nervous system or muscle delivery |
IL301563A IL301563A (en) | 2020-10-07 | 2021-10-07 | Recombinant adeno-associated viruses for cns or muscle delivery |
AU2021358546A AU2021358546A1 (en) | 2020-10-07 | 2021-10-07 | Recombinant adeno-associated viruses for cns or muscle delivery |
KR1020237010841A KR20230082613A (en) | 2020-10-07 | 2021-10-07 | Recombinant adeno-associated virus for CNS or muscle delivery |
US18/030,683 US20230374541A1 (en) | 2020-10-07 | 2021-10-07 | Recombinant adeno-associated viruses for cns or muscle delivery |
PCT/US2022/077816 WO2023060269A1 (en) | 2021-10-07 | 2022-10-07 | Recombinant adeno-associated viruses for targeted delivery |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063088988P | 2020-10-07 | 2020-10-07 | |
US63/088,988 | 2020-10-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022076750A2 true WO2022076750A2 (en) | 2022-04-14 |
WO2022076750A3 WO2022076750A3 (en) | 2022-05-27 |
Family
ID=78500754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/054058 WO2022076750A2 (en) | 2020-10-07 | 2021-10-07 | Recombinant adeno-associated viruses for cns or muscle delivery |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022076750A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023060269A1 (en) * | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for targeted delivery |
WO2023060272A3 (en) * | 2021-10-07 | 2023-06-15 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
WO2023225564A1 (en) * | 2022-05-18 | 2023-11-23 | The Broad Institute, Inc. | Engineered viral capsids with increased stability and methods of use thereof |
US11859200B2 (en) | 2020-05-13 | 2024-01-02 | Voyager Therapeutics, Inc. | AAV capsids with increased tropism to brain tissue |
WO2023242633A3 (en) * | 2022-06-14 | 2024-02-15 | Vectory B.V. | Recombinant aav capsid proteins |
Citations (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4526938A (en) | 1982-04-22 | 1985-07-02 | Imperial Chemical Industries Plc | Continuous release formulations |
WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
WO1996020698A2 (en) | 1995-01-05 | 1996-07-11 | The Board Of Regents Acting For And On Behalf Of The University Of Michigan | Surface-modified nanoparticles and method of making and using same |
US5622699A (en) | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
US5679377A (en) | 1989-11-06 | 1997-10-21 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
WO1999015154A1 (en) | 1997-09-24 | 1999-04-01 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release preparations |
WO1999020253A1 (en) | 1997-10-23 | 1999-04-29 | Bioglan Therapeutics Ab | Encapsulation method |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5916597A (en) | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
WO2002029056A2 (en) | 2000-10-06 | 2002-04-11 | Regents Of The University Of Michigan | Mini-dystrophin nucleic acid and peptide sequences |
WO2003042397A2 (en) | 2001-11-13 | 2003-05-22 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
WO2003052051A2 (en) | 2001-12-17 | 2003-06-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
WO2005033321A2 (en) | 2003-09-30 | 2005-04-14 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
WO2006068888A1 (en) | 2004-12-22 | 2006-06-29 | Raytheon Company | System and technique for calibrating radar arrays |
WO2006110689A2 (en) | 2005-04-07 | 2006-10-19 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
US7456683B2 (en) | 2005-06-09 | 2008-11-25 | Panasonic Corporation | Amplitude error compensating device and quadrature skew error compensating device |
WO2009104964A1 (en) | 2008-02-19 | 2009-08-27 | Amsterdam Molecular Therapeutics B.V. | Optimisation of expression of parvoviral rep and cap proteins in insect cells |
WO2010127097A1 (en) | 2009-04-30 | 2010-11-04 | The Trustees Of The University Of Pennsylvania | Compositions for targeting conducting airway cells comprising adeno-associated virus constructs |
US7892824B2 (en) | 2007-01-18 | 2011-02-22 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nNOS to the sarcolemma |
US20130224836A1 (en) | 2010-10-27 | 2013-08-29 | Jichi Medical University | Adeno-Associated Virus Virion for Gene Transfer to Nervous System Cells |
US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
WO2014172669A1 (en) | 2013-04-20 | 2014-10-23 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
WO2015013313A2 (en) | 2013-07-22 | 2015-01-29 | The Children's Hospital Of Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
US20150126588A1 (en) | 2012-05-09 | 2015-05-07 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
US9169299B2 (en) | 2011-08-24 | 2015-10-27 | The Board Of Trustees Of The Leleand Stanford Junior University | AAV capsid proteins for nucleic acid transfer |
US9193956B2 (en) | 2011-04-22 | 2015-11-24 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
WO2015197232A1 (en) | 2014-06-27 | 2015-12-30 | Genethon | Efficient systemic treatment of dystrophic muscle pathologies |
US20150374803A1 (en) | 2013-03-13 | 2015-12-31 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
WO2016049230A1 (en) | 2014-09-24 | 2016-03-31 | City Of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
WO2016115543A2 (en) | 2015-01-16 | 2016-07-21 | University Of Washington | Novel micro-dystrophins and related methods of use |
US20160215024A1 (en) | 2013-10-11 | 2016-07-28 | Massachusetts Eye & Ear Infirmary | Methods of Predicting Ancestral Virus Sequences and Uses Thereof |
US9409953B2 (en) | 2011-02-10 | 2016-08-09 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
WO2016177911A1 (en) | 2015-05-07 | 2016-11-10 | Royal Holloway & Bedford New College | Production of large-sized microdystrophins in an aav-based vector configuration |
US9585971B2 (en) | 2013-09-13 | 2017-03-07 | California Institute Of Technology | Recombinant AAV capsid protein |
US20170067908A1 (en) | 2014-04-25 | 2017-03-09 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
US9624282B2 (en) | 2012-11-26 | 2017-04-18 | The Curators Of The University Of Missouri | Microdystrophin peptides and methods for treating muscular dystrophy using the same |
WO2017070491A1 (en) | 2015-10-23 | 2017-04-27 | Applied Genetic Technologies Corporation | Ophthalmic formulations |
WO2017221145A1 (en) | 2016-06-21 | 2017-12-28 | Bamboo Therapeutics, Inc. | Optimized mini-dystrophin genes and expression cassettes and their use |
US9923120B2 (en) | 2015-09-26 | 2018-03-20 | Nichia Corporation | Semiconductor light emitting element and method of producing the same |
WO2018075798A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
WO2021108755A2 (en) | 2019-11-28 | 2021-06-03 | Regenxbio Inc. | Microdystrophin gene therapy constructs and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA038695B1 (en) * | 2017-02-15 | 2021-10-06 | Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл | Methods and compositions for gene transfer across the vasculature |
TW202102526A (en) * | 2019-04-04 | 2021-01-16 | 美商銳進科斯生物股份有限公司 | Recombinant adeno-associated viruses and uses thereof |
-
2021
- 2021-10-07 WO PCT/US2021/054058 patent/WO2022076750A2/en active Application Filing
Patent Citations (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4526938A (en) | 1982-04-22 | 1985-07-02 | Imperial Chemical Industries Plc | Continuous release formulations |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
US5679377A (en) | 1989-11-06 | 1997-10-21 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
WO1996020698A2 (en) | 1995-01-05 | 1996-07-11 | The Board Of Regents Acting For And On Behalf Of The University Of Michigan | Surface-modified nanoparticles and method of making and using same |
US5916597A (en) | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
US5622699A (en) | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
WO1999015154A1 (en) | 1997-09-24 | 1999-04-01 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release preparations |
WO1999020253A1 (en) | 1997-10-23 | 1999-04-29 | Bioglan Therapeutics Ab | Encapsulation method |
US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
US7125717B2 (en) | 1999-08-09 | 2006-10-24 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for their preparation and use |
WO2002029056A2 (en) | 2000-10-06 | 2002-04-11 | Regents Of The University Of Michigan | Mini-dystrophin nucleic acid and peptide sequences |
WO2003042397A2 (en) | 2001-11-13 | 2003-05-22 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
US8524446B2 (en) | 2001-11-13 | 2013-09-03 | The Trustees Of The University Of Pennsylvania | Method for detecting adeno-associated virus |
US8962332B2 (en) | 2001-12-17 | 2015-02-24 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
WO2003052051A2 (en) | 2001-12-17 | 2003-06-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
US7282199B2 (en) | 2001-12-17 | 2007-10-16 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US8318480B2 (en) | 2001-12-17 | 2012-11-27 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US7790449B2 (en) | 2001-12-17 | 2010-09-07 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor |
WO2005033321A2 (en) | 2003-09-30 | 2005-04-14 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
US7906111B2 (en) | 2003-09-30 | 2011-03-15 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor |
WO2006068888A1 (en) | 2004-12-22 | 2006-06-29 | Raytheon Company | System and technique for calibrating radar arrays |
WO2006110689A2 (en) | 2005-04-07 | 2006-10-19 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
US8999678B2 (en) | 2005-04-07 | 2015-04-07 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an AAV vector |
US7456683B2 (en) | 2005-06-09 | 2008-11-25 | Panasonic Corporation | Amplitude error compensating device and quadrature skew error compensating device |
US7892824B2 (en) | 2007-01-18 | 2011-02-22 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nNOS to the sarcolemma |
WO2009104964A1 (en) | 2008-02-19 | 2009-08-27 | Amsterdam Molecular Therapeutics B.V. | Optimisation of expression of parvoviral rep and cap proteins in insect cells |
WO2010127097A1 (en) | 2009-04-30 | 2010-11-04 | The Trustees Of The University Of Pennsylvania | Compositions for targeting conducting airway cells comprising adeno-associated virus constructs |
US9284357B2 (en) | 2009-05-28 | 2016-03-15 | University Of Massachusetts | AAV's and uses thereof |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
US20130224836A1 (en) | 2010-10-27 | 2013-08-29 | Jichi Medical University | Adeno-Associated Virus Virion for Gene Transfer to Nervous System Cells |
US9409953B2 (en) | 2011-02-10 | 2016-08-09 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
US9587282B2 (en) | 2011-04-22 | 2017-03-07 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
US9193956B2 (en) | 2011-04-22 | 2015-11-24 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
US20160376323A1 (en) | 2011-04-22 | 2016-12-29 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
US9458517B2 (en) | 2011-04-22 | 2016-10-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
US9169299B2 (en) | 2011-08-24 | 2015-10-27 | The Board Of Trustees Of The Leleand Stanford Junior University | AAV capsid proteins for nucleic acid transfer |
US20150126588A1 (en) | 2012-05-09 | 2015-05-07 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
US9624282B2 (en) | 2012-11-26 | 2017-04-18 | The Curators Of The University Of Missouri | Microdystrophin peptides and methods for treating muscular dystrophy using the same |
US20150374803A1 (en) | 2013-03-13 | 2015-12-31 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
WO2014172669A1 (en) | 2013-04-20 | 2014-10-23 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs |
US9840719B2 (en) | 2013-07-22 | 2017-12-12 | The Children's Hospital Of Philadelphia | Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissues |
WO2015013313A2 (en) | 2013-07-22 | 2015-01-29 | The Children's Hospital Of Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
US9585971B2 (en) | 2013-09-13 | 2017-03-07 | California Institute Of Technology | Recombinant AAV capsid protein |
US20160215024A1 (en) | 2013-10-11 | 2016-07-28 | Massachusetts Eye & Ear Infirmary | Methods of Predicting Ancestral Virus Sequences and Uses Thereof |
US20170051257A1 (en) | 2013-10-11 | 2017-02-23 | Massachusetts Eye And Ear Infirmary | Methods of predicting ancestral virus sequences and uses thereof |
US20170067908A1 (en) | 2014-04-25 | 2017-03-09 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
WO2015197232A1 (en) | 2014-06-27 | 2015-12-30 | Genethon | Efficient systemic treatment of dystrophic muscle pathologies |
WO2016049230A1 (en) | 2014-09-24 | 2016-03-31 | City Of Hope | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |
WO2016115543A2 (en) | 2015-01-16 | 2016-07-21 | University Of Washington | Novel micro-dystrophins and related methods of use |
WO2016177911A1 (en) | 2015-05-07 | 2016-11-10 | Royal Holloway & Bedford New College | Production of large-sized microdystrophins in an aav-based vector configuration |
US9923120B2 (en) | 2015-09-26 | 2018-03-20 | Nichia Corporation | Semiconductor light emitting element and method of producing the same |
WO2017070491A1 (en) | 2015-10-23 | 2017-04-27 | Applied Genetic Technologies Corporation | Ophthalmic formulations |
WO2017221145A1 (en) | 2016-06-21 | 2017-12-28 | Bamboo Therapeutics, Inc. | Optimized mini-dystrophin genes and expression cassettes and their use |
WO2018075798A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
WO2021108755A2 (en) | 2019-11-28 | 2021-06-03 | Regenxbio Inc. | Microdystrophin gene therapy constructs and uses thereof |
Non-Patent Citations (44)
Title |
---|
"Medical Applications of Controlled Release", 1974, CRC PRES. |
"Physician 's Desk Reference", 2002 |
ALBA ET AL.: "Gutless adenovirus: last generation adenovirus for gene therapy", GENE THERAPY, vol. 12, 2005, pages S18 - S27, XP008102765, DOI: 10.1038/sj.gt.3302612 |
ALBRIGHT ET AL., MAPPING THE STRUCTURAL DETERMINANTS REQUIRED FOR AAVRH. 10 TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER, 2018 |
APONTE-UBILLUS ET AL., APPL. MICROBIOL. BIOTECHNOL., vol. 102, 2018, pages 1045 - 1054 |
AURICCHIO ET AL., HUM. MOLEC. GENET., vol. 10, 2001, pages 3075 - 3081 |
BUCHWALD ET AL., SURGERY, vol. 88, 1980, pages 507 |
CLEEK ET AL.: "Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application", PRO. INTL. SYMP. CONTROL. REL. BIOACT. MATER., vol. 24, 1997 |
DOUAR ET AL.: "Deleterious effect of peptide insertions in a permissive site of the AAV2 capsid", VIROLOGY, vol. 309, 2003, pages 203 - 208, XP003001870 |
DUAN ET AL., J. VIROL., vol. 75, 2001, pages 7662 - 7671 |
DURING ET AL., ANN. NEUROL., vol. 25, 1989, pages 351 |
GEORGIADIS ET AL., GENE THERAPY, vol. 23, 2016, pages 857 - 862 |
GEORGIADIS ET AL., GENE THERAPY, vol. 25, 2018, pages 450 |
GILES ET AL., MAPPING AN ADENO-ASSOCIATED VIRUS 9-SPECIFIC NEUTRALIZING EPITOPE TO DEVELOP NEXT-GENERATION GENE DELIVERY VECTORS, 2018 |
GIROD ET AL.: "Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2", NATURE MEDICINE, vol. 3, no. 9, 1999, pages 1052 - 1056, XP002128040, DOI: 10.1038/71021 |
GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984 |
GRIFMAN ET AL.: "Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus Capsids", MOLECULAR THERAPY, vol. 3, no. 6, 2001, pages 964 - 975, XP002235294, DOI: 10.1006/mthe.2001.0345 |
HALBERT ET AL., J. VIROL., vol. 74, 2000, pages 1524 - 1532 |
HOWARD ET AL., J. NEUROSURG., vol. 71, 1989, pages 105 |
ISSA ET AL., PLOS ONE, vol. 8, no. 4, 2013, pages e60361 |
LAM ET AL.: "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery", PROC. INT'L. SYMP. CONTROL REL. BIOACT. MATER., vol. 24, 1997 |
LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533 |
LEVY ET AL., SCIENCE, vol. 228, 1985, pages 190 |
LOCHRIE ET AL.: "Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5", VIROLOGY, vol. 353, 2006, pages 68 - 82, XP024896378, DOI: 10.1016/j.virol.2006.05.023 |
MCCARTY ET AL., GENE THERAPY, vol. 8, no. 16, 2001, pages 1248 - 1254 |
NICKLIN ET AL.: "Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial Cells", MOLECULAR THERAPY, vol. 4, no. 2, 2001, pages 174 - 181, XP055129187, DOI: 10.1006/mthe.2001.0424 |
NING ET AL.: "Intratumoral Radioimmunotheraphy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel", RADIOTHERAPY & ONCOLOGY, vol. 39, 1996 |
PONNAZHAGAN ET AL., J. OF VIROLOGY, vol. 75, no. 19, 2001, pages 9493 - 9501 |
POWELLRIVERA-SOTO, DISCOV. MED., vol. 19, no. 102, 2015, pages 49 - 57 |
PUZZO ET AL., SCI. TRANSL. MED., vol. 29, no. 9, 2017, pages 418 |
QUAX ET AL., MOL CELL, vol. 59, 2015, pages 149 - 161 |
RANGERPEPPAS, J., MACROMOL. SCI. REV. MACROMOL. CHEM., vol. 23, 1983, pages 61 |
SADE, H., PLOS ONE, vol. 9, no. 4, 2014, pages e96340 |
SAUDEK ET AL., N. ENGL. J. MED., vol. 321, 1989, pages 574 |
SEFTON, CRC CRIT. REF. BIOMED. ENG., vol. 14, 1987, pages 20 |
SHEN ET AL., GLYCAN BINDING AVIDITY DETERMINES THE SYSTEMIC FATE OF ADENO-ASSOCIATED VIRUS TYPE 9, 2012 |
SHIBARTLETT: "RGD Inclusion in VP3 Provides Adeno-Associated Virus Type 2 (AAV2)-Based Vectors with a Heparan Sulfate-Independent Cell Entry Mechanism", MOLECULAR THERAPY, vol. 7, no. 4, 2003, pages 515525, XP002503474, DOI: 10.1016/S1525-0016(03)00042-X |
SONG ET AL.: "Antibody Mediated Lung Targeting of Long-Circulating Emulsions", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, vol. 50, 1995 |
WU ET AL.: "Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism", J OF VIROLOGY, vol. 74, no. 18, 2000, pages 8635 - 8647, XP055548655, DOI: 10.1128/JVI.74.18.8635-8647.2000 |
WU, HUMAN GENE THERAPY, vol. 18, no. 2, 2007, pages 171 - 82 |
YOST ET AL.: "Structure-guided engineering of surface exposed loops on AAV Capsids. 2019", ASGCT ANNUAL MEETING |
ZHANG, X.: "Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration", BIOMATERIALS, vol. 176, 2018, pages 71 - 83 |
ZINN ET AL., CELL REP., vol. 12, no. 6, 2015, pages 1056 - 1068 |
ZOLOTUKHIN ET AL., METHODS, vol. 28, 2002, pages 158 - 167 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11859200B2 (en) | 2020-05-13 | 2024-01-02 | Voyager Therapeutics, Inc. | AAV capsids with increased tropism to brain tissue |
WO2023060269A1 (en) * | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for targeted delivery |
WO2023060272A3 (en) * | 2021-10-07 | 2023-06-15 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
WO2023225564A1 (en) * | 2022-05-18 | 2023-11-23 | The Broad Institute, Inc. | Engineered viral capsids with increased stability and methods of use thereof |
WO2023242633A3 (en) * | 2022-06-14 | 2024-02-15 | Vectory B.V. | Recombinant aav capsid proteins |
Also Published As
Publication number | Publication date |
---|---|
WO2022076750A3 (en) | 2022-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220186256A1 (en) | Recombinant adeno-associated viruses and uses thereof | |
WO2022076750A2 (en) | Recombinant adeno-associated viruses for cns or muscle delivery | |
US20230381341A1 (en) | Adeno-associated viruses for ocular delivery of gene therapy | |
WO2021021661A1 (en) | Engineered nucleic acid regulatory element and methods of uses thereof | |
CA3162020A1 (en) | Compositions for treating friedreich's ataxia | |
EP3829619A1 (en) | Treatment of mucopolysaccharidosis iva | |
CN113438954A (en) | Compositions useful for treating GM1 gangliosidosis | |
EP4225778A2 (en) | Recombinant adeno-associated viruses for cns or muscle delivery | |
WO2023060269A1 (en) | Recombinant adeno-associated viruses for targeted delivery | |
WO2023201277A1 (en) | Recombinant adeno-associated viruses for cns tropic delivery | |
WO2023060272A2 (en) | Recombinant adeno-associated viruses for cns tropic delivery | |
WO2024044725A2 (en) | Recombinant adeno-associated viruses and uses thereof | |
EP4089171A1 (en) | Recombinant tert-encoding viral genomes and vectors | |
US20230064077A1 (en) | Treatment of mucopolysaccharidosis iva | |
WO2023147304A1 (en) | Aav capsids for improved heart transduction and detargeting of liver | |
CA3185281A1 (en) | Compositions useful for treatment of charcot-marie-tooth disease | |
WO2023077092A1 (en) | Engineered nucleic acid regulatory elements and methods and uses thereof | |
CN116445492A (en) | Gene therapy medicine and method for X chromosome linked adrenoleukodystrophy | |
CN116568815A (en) | Adeno-associated virus for ocular delivery of gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21802102 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 3193685 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023519433 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180066787.X Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021802102 Country of ref document: EP Effective date: 20230508 |
|
ENP | Entry into the national phase |
Ref document number: 2021358546 Country of ref document: AU Date of ref document: 20211007 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021802102 Country of ref document: EP Effective date: 20230508 |